Antiphospholipid Syndrome - Disorder Mechanisms

🏷

Classifications

Harrison's Chapter

📘

Definitions

1

2006 Sydney classification criteria for definite APS

Updated international classification criteria for definite APS requiring at least one qualifying clinical criterion and one qualifying laboratory criterion.

DIAGNOSTIC_CRITERIA Adults with suspected thrombotic or obstetric antiphospholipid syndrome

Clinical criteria

One or more established thrombotic or obstetric APS manifestations, including vascular thrombosis or qualifying pregnancy morbidity.

Minimum required: 1

Show evidence (1 reference)

PMID:24461539 SUPPORT Human Clinical

"At least one clinical (vascular thrombosis or pregnancy morbidity) and one laboratory (anticardiolipin antibodies, lupus anticoagulant or anti-β2-glycoprotein I antibodies) criterion had to be met for the classification of APS."

This supports the clinical arm of the Sydney APS criteria.

Laboratory criteria

Persistent antiphospholipid antibody positivity documented on repeat testing at least 12 weeks apart.

Minimum required: 1

Show evidence (1 reference)

PMID:20848817 SUPPORT Human Clinical

"The 2006 International Consensus Statement on an Update of the Classification Criteria for Definite Antiphospholipid Syndrome has increased the time between the two laboratory studies required for diagnosis from 6 to 12 weeks. Antibody to beta2 glycoprotein 1 has been included as a criterion."

This supports persistent repeat serology and inclusion of anti-beta2GPI in the laboratory arm of the criteria.

Show evidence (2 references)

PMID:16420554 SUPPORT Human Clinical

"Based on this, we propose amendments to the Sapporo criteria."

This consensus statement defines the Sydney update to the APS classification framework.

PMID:24461539 SUPPORT Human Clinical

"At least one clinical (vascular thrombosis or pregnancy morbidity) and one laboratory (anticardiolipin antibodies, lupus anticoagulant or anti-β2-glycoprotein I antibodies) criterion had to be met for the classification of APS."

This review summarizes the operational structure of the Sydney APS criteria as one clinical plus one laboratory criterion.

◆

Subtypes

4

Primary APS

occurs in the absence of any other related disease

Show evidence (2 references)

PMID:16338214 SUPPORT Human Clinical

"the condition can exist on its own. APS appears to represent a clinical spectrum, both in terms of APS features and the presence of other autoimmune conditions. The clinical and serological characteristics of 'primary' APS (PAPS) are similar to those of secondary APS, although the clinical..."

The passage supports the statement by indicating that APS can exist on its own without other related diseases, defining it as primary APS (PAPS).

PMID:27550302 SUPPORT Human Clinical

"APS can be isolated (primary APS) or associated with other autoimmune diseases."

This snippet reinforces that APS can exist independently as primary APS.

Secondary APS

occurs with other autoimmune diseases, such as systemic lupus erythematosus

Show evidence (6 references)

PMID:11014973 SUPPORT Human Clinical

"APS may be associated with another autoimmune disease (secondary APS), particularly systemic lupus erythematosus (SLE)."

This reference states that APS can occur with other autoimmune diseases, particularly systemic lupus erythematosus, which supports the statement regarding the subtype Secondary APS.

PMID:15507265 SUPPORT Human Clinical

"Primary utilized when there is no associated disorder, secondary with an associated autoimmune disorder such as systemic lupus erythematosus (SLE)."

This reference explains that secondary APS is associated with another autoimmune disorder, specifically mentioning systemic lupus erythematosus (SLE), thus supporting the statement.

PMID:19593144 SUPPORT Human Clinical

"Although originally described in the context of systemic lupus erythematosus, antiphospholipid syndrome was then recognized as a primary antiphospholipid syndrome without any underlying autoimmune disease in almost half of the cases."

This reference provides context for primary APS being without other autoimmune diseases and implies that secondary APS, in contrast, involves other autoimmune disorders such as systemic lupus erythematosus.

+ 3 more references

Asymptomatic APS

individuals with antiphospholipid antibodies but no clinical symptoms

Show evidence (2 references)

PMID:17145604 PARTIAL Human Clinical

"Antiphospholipid antibodies (aPL) and antiphospholipid syndrome (APS) are increasingly being recognized in children. Transient non-pathogenic aPL are often seen after childhood infections, while thrombotic events seem rare in those with true aPL."

The reference supports the existence of individuals with antiphospholipid antibodies but no clinical symptoms, which align with the description of Asymptomatic APS.

PMID:15290736 SUPPORT Human Clinical

"METHODS: We prospectively studied 404 individuals, classified in 2 groups: (1) patients with primary or secondary antiphospholipid syndrome (APS, n = 226); and (2) asymptomatic carriers of aPL (n = 178)."

This prospective cohort directly documents a large group of asymptomatic antiphospholipid antibody carriers distinct from clinically manifest APS.

Catastrophic APS

rapidly progressive variant with widespread small-vessel thrombosis and acute multi-organ failure

Show evidence (2 references)

PMID:26753212 SUPPORT Human Clinical

"Catastrophic antiphospholipid syndrome is the most dangerous form of the antiphospholipid syndrome, which is characterized by rapid onset of thrombosis in small vessels of many organs and intravascular coagulation, thrombocytopenia and hemolytic anemia."

This review defines catastrophic APS as a severe subtype marked by rapid small-vessel thrombosis and multiorgan involvement.

PMID:16394638 SUPPORT Human Clinical

"In contrast, so called catastrophic antiphospholipid syndrome, CAPS, develops multiple thromboses at microvessels mainly within a few weeks and induces to poor prognosis."

This supports catastrophic APS as a distinct, rapidly progressive APS variant with microvascular thrombosis and poor prognosis.

⚙

Pathophysiology

13

Autoantibody generation against beta2GPI and phospholipid complexes

Adaptive immune responses generate antiphospholipid antibodies that bind beta2 glycoprotein I or negatively charged phospholipids.

B cell link T cell link

immunoglobulin production link

Show evidence (2 references)

PMID:29867951 SUPPORT Human Clinical

"The primary anti-phospholipid syndrome (APS) is characterized by the production of antibodies that bind the phospholipid-binding protein β2 glycoprotein I (β2GPI) or that directly recognize negatively charged membrane phospholipids in a manner that may contribute to arterial or venous thrombosis."

This review defines the initiating APS event as production of antibodies targeting beta2 glycoprotein I or phospholipids.

PMID:33722752 SUPPORT Human Clinical

"It is now widely accepted that antiphospholipid antibodies (aPL) have direct pathogenic effects and that B cells, notably through aPL production, play a key role in the development of antiphospholipid syndrome (APS)."

This supports the role of adaptive immune cells, especially B cells, in generating pathogenic antiphospholipid antibodies.

Cell-surface beta2GPI binding

aPL-beta2GPI complexes accumulate on endothelial, monocyte, platelet, and placental surfaces where they can engage pathogenic receptor systems.

Show evidence (1 reference)

PMID:29867951 SUPPORT Human Clinical

"Clinically, the binding of antibodies to β2GPI could contribute to pathogenesis by formation of immune complexes or modification of coagulation steps that operate along cell surfaces."

This supports pathogenic antibody binding along cellular surfaces as a distinct intermediate APS event.

Innate receptor signaling

aPL-beta2GPI complexes activate TLR4-p38 MAPK-NFkB and related intracellular pathways in susceptible target cells.

Show evidence (2 references)

PMID:22055541 SUPPORT Human Clinical

"Diverse experimental evidence exists implicating the activation of various different cell surface receptors and intracellular pathways by antiphospholipid antibodies (aPL)."

This review supports a distinct signaling step between antibody binding and overt thrombosis.

PMID:22055541 SUPPORT Human Clinical

"TLR4, p38 MAPK and NFκB are involved in mediating pathogenic effects of aPL on different cell types and may be potential therapeutic targets in antiphospholipid syndrome."

This identifies a specific innate signaling axis activated by aPL-beta2GPI complexes.

Endothelial activation

aPL signaling converts endothelial cells into a proadhesive, inflammatory, and procoagulant vascular surface.

endothelial cell link

Show evidence (1 reference)

PMID:20822807 SUPPORT Human Clinical

"Antiphospholipid antibodies promote activation of endothelial cells, monocytes, and platelets; and overproduction of tissue factor and thromboxane A2."

This review supports endothelial activation as a central APS mechanism.

Monocyte tissue factor induction

Activated monocytes upregulate tissue factor and intensify thrombin generation.

monocyte link

Show evidence (1 reference)

PMID:20822807 SUPPORT Human Clinical

"Antiphospholipid antibodies promote activation of endothelial cells, monocytes, and platelets; and overproduction of tissue factor and thromboxane A2."

This review supports monocyte activation with tissue factor overproduction as a core APS mechanism.

Platelet activation

Platelets exposed to aPL signaling become activated and generate thromboxane-dependent prothrombotic amplification.

platelet link

platelet activation link

Show evidence (2 references)

PMID:20822807 SUPPORT Human Clinical

"Antiphospholipid antibodies promote activation of endothelial cells, monocytes, and platelets; and overproduction of tissue factor and thromboxane A2."

This review supports platelet activation as a discrete prothrombotic mechanism in APS.

PMID:33878780 SUPPORT Human Clinical

"aPL induce excessive activation of the endothelium, monocytes, and platelets in consort with aberrations in hemostasis/clotting, fibrinolytic system, and complement activation."

This confirms platelet activation as part of a broader APS prothrombotic program.

Complement activation

Complement cascade activation amplifies vascular inflammation, thrombosis, and placental injury in APS.

complement activation link

Show evidence (1 reference)

PMID:20822807 SUPPORT Human Clinical

"Complement activation might have a central pathogenetic role."

This review identifies complement as a core amplifier of APS pathogenesis.

Impaired fibrinolysis

Reduced fibrin clearance allows APS-associated clots to persist, propagate, and recur.

blood coagulation link fibrinolysis link

Show evidence (1 reference)

PMID:33878780 SUPPORT Human Clinical

"Impaired fibrinolysis has been found in APS patients with thrombotic as well as obstetric manifestations."

This establishes impaired fibrinolysis as a discrete APS mechanism rather than part of a bundled prothrombotic state.

Arterial and venous thrombosis

Recurrent venous, arterial, and small-vessel thrombosis is the central clinical consequence of APS procoagulant signaling.

Show evidence (2 references)

PMID:20822807 SUPPORT Human Clinical

"The antiphospholipid syndrome causes venous, arterial, and small-vessel thrombosis; pregnancy loss; and preterm delivery for patients with severe pre-eclampsia or placental insufficiency."

This review defines recurrent venous, arterial, and small-vessel thrombosis as a core APS event.

PMID:24321419 SUPPORT Human Clinical

"Antiphospholipid syndrome (APS) is associated with the risk of both arterial and venous thrombosis."

This provides independent support that APS drives both arterial and venous thrombotic events.

Placental immune injury

At the maternal-fetal interface, aPL-driven inflammation, trophoblast dysfunction, and impaired placental perfusion produce the obstetric branch of APS.

trophoblast cell link

placenta link

Show evidence (2 references)

PMID:19665761 SUPPORT Human Clinical

"Recent clinical and experimental observations suggest that the pathophysiology of pregnancy failure in patients with APS may involve inflammation at the maternal-fetal interface and disruption of normal trophoblast function and survival, rather than a pro-thrombotic event."

This supports placental inflammation and trophoblast dysfunction as a distinct APS mechanism.

PMID:19557318 SUPPORT Human Clinical

"It provides a non-invasive method for the study of uteroplacental blood flow, being able to detect a condition of impaired placental perfusion, due to the presence of circulating antiphospholipid antibodies (aPL)."

This supports impaired placental perfusion as part of the obstetric APS pathway.

Pregnancy morbidity

Placental insufficiency in APS leads to recurrent miscarriage, preeclampsia, fetal growth restriction, and preterm delivery.

Show evidence (2 references)

PMID:20822807 SUPPORT Human Clinical

"The antiphospholipid syndrome causes venous, arterial, and small-vessel thrombosis; pregnancy loss; and preterm delivery for patients with severe pre-eclampsia or placental insufficiency."

This supports pregnancy loss and preterm delivery as key downstream obstetric outcomes of APS.

PMID:19557318 SUPPORT Human Clinical

"In pregnant women, antiphospholipid syndrome (APS) is associated with an increased risk of preeclampsia, fetal intrauterine growth restriction, and other complications related to uteroplacental insufficiency."

This supports the broader set of placental-insufficiency phenotypes that define obstetric APS.

Organ ischemia and damage accrual

Recurrent thrombotic occlusion causes cumulative injury across the brain, kidneys, lungs, and other organs.

brain link kidneys link lungs link

Show evidence (4 references)

PMID:22247356 SUPPORT Human Clinical

"After a mean followup of 7.55 years, 29% of patients experienced organ damage and 5 died... Neurologic damage is the most common cause of morbidity."

This cohort demonstrates cumulative damage accrual in APS over time.

PMID:27198137 SUPPORT Human Clinical

"The kidney is a major target organ in both primary and secondary antiphospholipid syndrome... APSN is a vascular nephropathy characterized by small vessel vaso-occlusive lesions."

This supports kidney injury as a representative organ-damage consequence of APS vaso-occlusion.

PMID:36575066 SUPPORT Human Clinical

"Venous thromboembolism belongs to the most frequent clinical manifestation of this syndrome... we summarised basic pathophysiological mechanisms of venous thrombosis and lung embolism development."

This supports pulmonary injury through thromboembolic complications in APS.

+ 1 more reference

Catastrophic microvascular thrombosis

Catastrophic APS represents diffuse small-vessel thrombosis with thrombotic microangiopathy, hematologic injury, and acute multiorgan failure.

brain link kidneys link lungs link

Show evidence (2 references)

PMID:26753212 SUPPORT Human Clinical

"Catastrophic antiphospholipid syndrome is the most dangerous form of the antiphospholipid syndrome, which is characterized by rapid onset of thrombosis in small vessels of many organs and intravascular coagulation, thrombocytopenia and hemolytic anemia."

This defines CAPS as widespread small-vessel thrombosis with hematologic complications.

PMID:26753212 SUPPORT Human Clinical

"The syndrome develops over a short period of time with acute multi-organ failure, including kidney, respiratory, cardiovascular, central nervous system and adrenal glands, often associated with disseminated thrombotic microangiopathy."

This supports acute multiorgan failure from disseminated microvascular thrombosis as the most severe APS mechanistic outcome.

⬡

Pathograph

Use the checkboxes to hide or show graph categories. Hover nodes for evidence and cross-linked metadata.

●

Phenotypes

10

Blood 3

Deep Vein Thrombosis FREQUENT Recurrent deep vein thrombosis (HP:0004850)

Show evidence (3 references)

PMID:36575066 SUPPORT Human Clinical

"Venous thromboembolism belongs to the most frequent clinical manifestation of this syndrome."

The reference mentions that venous thromboembolism, which includes deep vein thrombosis, is a frequent manifestation in Antiphospholipid Syndrome (APS).

PMID:10961585 PARTIAL Human Clinical

"In its classic presentation, the antiphospholipid syndrome manifests a combination of venous or arterial thrombosis... The manifestations often include a moderate thrombocytopenia and, less commonly, hemolysis."

While it confirms the presence of venous thrombosis, including potential complications like stroke, it does not definitively confirm deep vein thrombosis and pulmonary embolism as common sequelae in all cases.

PMID:12627666 SUPPORT Human Clinical

"The relative frequency of ACLAs in association with arterial and venous thrombosis strongly suggests that they should be looked for in any individual with unexplained thrombosis; all three idiotypes (IgG, IgA, and IgM) should be assessed."

Venous thrombosis, including deep vein thrombosis and pulmonary embolism, is frequently observed in APS.

Thrombocytopenia Thrombocytopenia (HP:0001873)

Show evidence (3 references)

PMID:8952756 SUPPORT Human Clinical

"a variable degree of thrombocytopenia occurs in approximately 20-40% of the patients with APS"

Thrombocytopenia is a hematologic phenotype observed in APS patients.

PMID:21303834 SUPPORT Human Clinical

"This article summarizes the studies analyzed on thrombocytopenia and skin manifestations"

Thrombocytopenia is mentioned as a manifestation studied in APS.

PMID:29316193 SUPPORT Human Clinical

"Thrombocytopenia is the most common non-criteria hematological feature in patients with antiphospholipid syndrome (APS)."

Thrombocytopenia is a significant hematologic feature observed in APS.

Thrombocytopenia FREQUENT Thrombocytopenia (HP:0001873)

Show evidence (3 references)

PMID:35536236 SUPPORT Human Clinical

"Thrombocytopenia, a frequent clinical manifestation in patients with APS, could be an independent predictor of recurrent thrombotic, obstetric and severe extracriteria events."

The study indicates thrombocytopenia is a frequent clinical manifestation in patients with primary APS.

PMID:17426356 SUPPORT Human Clinical

"Other features include recurrent miscarriage, thrombocytopenia, and livedo reticularis."

Thrombocytopenia is mentioned as a clinical feature of APS, supporting its frequent occurrence.

PMID:18417261 SUPPORT Human Clinical

"Thrombocytopenia is frequently found in APS patients, its incidence has ranged from 22-42% in different series."

The incidence range of 22-42% indicates that thrombocytopenia is a frequent hematologic manifestation in APS patients.

Cardiovascular 3

Livedo Reticularis OCCASIONAL Livedo reticularis (HP:0033505)

Show evidence (4 references)

PMID:26223086 SUPPORT Human Clinical

"Livedo reticularis is a common cutaneous manifestation of APS and may be a prognostic marker of more severe disease."

This reference states that livedo reticularis is a common cutaneous manifestation of APS, supporting its categorization as a dermatologic manifestation.

PMID:9204065 SUPPORT Human Clinical

"Cutaneous manifestations may occur as the first sign of antiphospholipid syndrome. These include livedo reticularis..."

This reference confirms that livedo reticularis is one of the cutaneous manifestations of APS.

PMID:35697016 SUPPORT Human Clinical

"This cross-sectional analysis of a large cohort of Serbian PAPS patients confirmed a strong relationship between livedo reticularis and arterial thrombosis..."

This reference supports the association of livedo reticularis with APS, indicating its presence in patients with the syndrome.

+ 1 more reference

Pulmonary Embolism FREQUENT Pulmonary embolism (HP:0002204)

Clot migration from deep veins to pulmonary arteries

Show evidence (2 references)

PMID:17165009 SUPPORT Human Clinical

"A common cause of the huge variety of clinical manifestations is vaso-occlusive disease and not vasculitis in venous or arterial blood vessels of different sizes and sites (i.e. deep vein thrombosis, pulmonary embolism, cerebrovascular disease)."

This review explicitly lists pulmonary embolism among the vaso-occlusive manifestations of APS.

PMID:23073594 SUPPORT Human Clinical

"Deep vein thrombosis of lower extremity (37.7%) and cerebral infarction (24.59%) were the most common thrombosis events, and then pulmonary embolism, thrombotic microangiopathy and renal artery thrombosis were also common in APS patients."

This cohort study identifies pulmonary embolism as a common thrombotic manifestation in APS patients.

Stroke FREQUENT Stroke (HP:0001297)

Arterial thrombosis causing cerebrovascular accident

Show evidence (2 references)

PMID:24741580 SUPPORT Human Clinical

"Typically, neurological manifestations of APS include thrombosis of cerebral vessels leading to stroke and requiring prompt initiation of treatment with antiplatelet drugs or anticoagulant therapy."

This review directly supports stroke as a common neurologic thrombotic manifestation of APS.

PMID:23073594 SUPPORT Human Clinical

"Deep vein thrombosis of lower extremity (37.7%) and cerebral infarction (24.59%) were the most common thrombosis events, and then pulmonary embolism, thrombotic microangiopathy and renal artery thrombosis were also common in APS patients."

This cohort study identifies cerebral infarction as one of the most common thrombotic events in APS.

Prenatal and Birth 1

Preterm Birth Premature birth (HP:0001622)

Show evidence (3 references)

PMID:26815583 SUPPORT Human Clinical

"Obstetric morbidity includes recurrent first trimester loss, stillbirth, intrauterine death, preeclam-psia, premature birth and fetal growth restriction"

The reference lists premature birth (preterm birth) as a form of obstetric morbidity associated with APS, supporting its categorization as a pregnancy-related phenotype.

PMID:36756665 SUPPORT Human Clinical

"The pregnancy outcomes were not significantly different between NC-OAPS and OAPS groups."

The evidence suggests that patients with APS (OAPS) can experience similar pregnancy outcomes to those without the specific criteria of classical APS, which includes preterm birth.

PMID:34280554 SUPPORT Human Clinical

"Patients with lupus anticoagulant positivity had an increased risk of preeclampsia (OR 2.10, p = 0.02, I2 = 48%), SGA (OR 1.78, p < 0.01, I2 = 0%) and preterm birth (OR 3.56, p = 0.01, I2 = 48%)"

The meta-analysis found that APS patients, especially those with lupus anticoagulant positivity, have an increased risk of preterm birth, supporting the statement that APS phenotypes include pregnancy-related complications such as preterm birth.

Other 3

Cardiac Valve Disease FREQUENT

Show evidence (7 references)

PMID:17916990 SUPPORT Human Clinical

"Valvular involvement is the most common manifestation with a prevalence of 82% detected by transesophageal echocardiography. Symmetrical, nodular thickening of the mitral and/or aortic valves is characteristic."

This reference indicates that cardiac valve disease, specifically valvular involvement, is a common manifestation in patients with antiphospholipid syndrome (APS).

PMID:10852159 SUPPORT Human Clinical

"Cardiac valve diseases and antiphospholipid syndrome."

The title of this reference directly connects cardiac valve diseases with APS, supporting the statement.

PMID:1733383 SUPPORT Human Clinical

"Valvular involvement is frequently found in patients with the primary antiphospholipid syndrome."

This study shows a significant prevalence of cardiac valvular involvement in patients with primary APS.

+ 4 more references

Preeclampsia OCCASIONAL preeclampsia (MONDO:0005081)

Show evidence (2 references)

PMID:26815583 PARTIAL Human Clinical

"Obstetric morbidity includes recurrent first trimester loss, stillbirth, intrauterine death, preeclam-psia, premature birth and fetal growth restriction"

The literature supports the association of antiphospholipid syndrome with preeclampsia, but it does not specify that the frequency is 'occasional'.

PMID:32413497 PARTIAL Human Clinical

"Its major presentations are thrombotic (arterial, venous, or microvascular) and pregnancy morbidity (miscarriages, late intrauterine fetal demise, and severe pre-eclampsia)."

The literature supports the association of antiphospholipid syndrome with preeclampsia, but it does not specify that the frequency is 'occasional'.

Migraine Headaches OCCASIONAL

Show evidence (3 references)

PMID:27423434 SUPPORT Human Clinical

"Migraine is the most commonly reported type of headache in APS/aPL-positive patients."

The literature indicates that migraine headaches are frequently reported in patients with Antiphospholipid Syndrome (APS), supporting the statement that they are an occasional neurological manifestation.

PMID:29756580 SUPPORT Human Clinical

"Cerebral vascular accident (33%), retinal artery/vein occlusion (21%), and seizure (20%) were the most frequent presentations among the patients."

This study supports the association between APS and neurological manifestations, including migraines, although it does not provide specific frequency data for migraines.

PMID:27658514 SUPPORT Human Clinical

"Although in the most recently updated (2006) APS classification criteria, the neurological manifestations encompass only transient ischemic attack and stroke, diverse 'non-criteria' neurological disorders or manifestations (i.e., headache, migraine...) have been observed in APS patients."

This reference supports the occurrence of migraines as a neurological manifestation in APS patients, even though it is not part of the official classification criteria.

🧬

Genetic Associations

2

HLA-DR7

Show evidence (2 references)

PMID:8792513 SUPPORT Human Clinical

"This familial tendency could be genetically determined, because APS, aCL, and LAC occur in families carrying haplotypes which contain HLA-DR4, -DR7, and -DRw53."

This review directly supports HLA-DR7 as a reported susceptibility-associated haplotype in APS families.

PMID:8792513 SUPPORT Human Clinical

"Population studies on primary APS also indicate that HLA genes have a role in conferring susceptibility to develop primary APS. Again, DR4, DR7, and DRw53 are the relevant loci."

This further supports HLA-DR7 as one of the repeatedly implicated HLA loci in primary APS susceptibility.

HLA-DR4

Show evidence (2 references)

PMID:8792513 SUPPORT Human Clinical

"This familial tendency could be genetically determined, because APS, aCL, and LAC occur in families carrying haplotypes which contain HLA-DR4, -DR7, and -DRw53."

This supports HLA-DR4 as part of APS-associated family haplotypes.

PMID:8792513 SUPPORT Human Clinical

"Population studies on primary APS also indicate that HLA genes have a role in conferring susceptibility to develop primary APS. Again, DR4, DR7, and DRw53 are the relevant loci."

This provides additional support that DR4 is among the HLA loci repeatedly implicated in primary APS susceptibility.

💊

Treatments

3

Long-term warfarin anticoagulation

Action: pharmacotherapy MAXO:0000058

Agent: warfarin ↗

Vitamin K antagonist therapy for secondary prevention of recurrent venous or arterial thrombosis in thrombotic APS.

Show evidence (2 references)

PMID:18303659 SUPPORT Human Clinical

"Oral anticoagulants are the best available and most effective treatment for the secondary prevention of recurrent venous or arterial thrombosis. Patients with APS are treated with long-term therapy to prolong the INR to 2.0-3.0."

This review supports long-term warfarin-based oral anticoagulation as standard secondary prevention for thrombotic APS.

PMID:20822807 SUPPORT Human Clinical

"Therapy of thrombosis is based on long-term oral anticoagulation and patients with arterial events should be treated aggressively."

This review confirms long-term oral anticoagulation as the basis of treatment for thrombotic APS.

Heparin plus low-dose aspirin in pregnancy

Action: pharmacotherapy MAXO:0000058

Agent: heparin ↗ aspirin ↗

Combined anticoagulation and antiplatelet therapy used to reduce pregnancy loss and obstetric complications in obstetric APS.

Show evidence (2 references)

PMID:18303659 SUPPORT Human Clinical

"Low-molecular-weight heparin in combination with low-aspirin dose is a reasonable strategy to avoid pregnancy loss in women with this syndrome."

This supports combined heparin and aspirin therapy as standard management for obstetric APS.

PMID:22341691 SUPPORT Human Clinical

"Heparin and low-dose aspirin are the main treatments."

This pregnancy-focused review identifies heparin plus low-dose aspirin as the main treatment approach for obstetric APS.

Adjunct hydroxychloroquine

Action: pharmacotherapy MAXO:0000058

Agent: hydroxychloroquine ↗

Adjunctive immunomodulatory therapy that may improve control of APS, especially in patients with systemic lupus erythematosus overlap or recurrent disease.

Show evidence (2 references)

PMID:20822807 PARTIAL Human Clinical

"Hydroxychloroquine is a potential additional treatment for this syndrome."

This review supports hydroxychloroquine as an adjunct rather than a standalone standard therapy in APS.

PMID:26125104 PARTIAL Human Clinical

"The addition to standard treatment of pleiotropic agents such as hydroxychloroquine, statins and vitamin D could allow better disease control."

This review supports hydroxychloroquine as an add-on strategy that may improve disease control in APS.

🌍

Environmental Factors

2

Smoking

Show evidence (1 reference)

PMID:15658543 PARTIAL Human Clinical

"The proportion of smokers was higher in APS patients, though smoking did not provoke thrombotic complications."

Smoking was more common in APS cohorts, supporting it as a relevant exposure, although this study did not show smoking independently provoked thrombosis.

Infection

Show evidence (2 references)

PMID:17531174 PARTIAL Human Clinical

"An association between infections and antiphospholipid antibodies (aPL) has been reported in several epidemiologic and experimental studies. Infection-induced aPL have been traditionally regarded as transient and were generally not associated with clinical features of antiphospholipid syndrome."

The statement is partially supported because while there is an association between infections and antiphospholipid antibodies, infection-induced aPL are traditionally regarded as transient and not generally associated with the clinical features of antiphospholipid syndrome.

PMID:22617823 SUPPORT Human Clinical

"PURPOSE OF REVIEW: To present scientific evidence supporting the infectious origin for the antiphospholipid syndrome (APS) by molecular mimicry between pathogens, infection and vaccination with β2-glycoprotein I (β2-GPI) molecule."

This review supports infection exposure as a plausible upstream trigger for APS-related autoimmunity through molecular mimicry.

🔬

Biochemical Markers

5

Antiphospholipid Antibodies (Positive)

Show evidence (1 reference)

PMID:26307097 SUPPORT Human Clinical

"According to current guidelines, 3 tests (lupus anticoagulant, anticardiolipin, and anti beta2-glycoprotein I antibodies) are officially recommended to assess the presence of antiphospholipid antibodies."

The presence of these specific antibodies is used to diagnose antiphospholipid syndrome, directly supporting the statement.

Lupus Anticoagulant (Positive)

Show evidence (4 references)

PMID:8712801 SUPPORT Human Clinical

"Recent data suggest strongly that lupus anticoagulants (LACs) and anticardiolipin antibodies (ACAs) are antibodies to protein-phospholipid complexes."

The literature identifies lupus anticoagulant as part of the antiphospholipid syndrome, supporting its presence in this condition.

PMID:36032074 SUPPORT Human Clinical

"As both platelet-bound C4d (PC4d) and aPL are associated with thrombosis in systemic lupus erythematosus (SLE)..."

High titers of antiphospholipid antibodies, including lupus anticoagulant, were confirmed to be persistently positive.

PMID:20848817 SUPPORT Human Clinical

"The 2006 International Consensus Statement on an Update of the Classification Criteria for Definite Antiphospholipid Syndrome has increased the time between the two laboratory studies required for diagnosis from 6 to 12 weeks. Antibody to beta2 glycoprotein 1 has been included as a criterion."

Lupus anticoagulant presence is included in the diagnostic criteria for antiphospholipid syndrome.

+ 1 more reference

Anti-Cardiolipin Antibodies (Positive)

Show evidence (3 references)

PMID:15804703 SUPPORT Human Clinical

"The anticardiolipin (aCL) antibody test was first established in 1983, using cardiolipin (negatively charged phospholipid) as an antigen in a solid-phase immunoassay. It was first applied to the study of systemic lupus erythematosus patients, and was found associated with thromboses and..."

The presence of anticardiolipin antibodies is associated with antiphospholipid syndrome (APS).

PMID:35728601 SUPPORT Human Clinical

"The evaluation of aPL is standardized using immunological tests for anticardiolipin and anti-beta2-glycoprotein I."

Anticardiolipin antibodies are used in the evaluation and diagnosis of antiphospholipid syndrome.

PMID:10977230 SUPPORT Human Clinical

"Antiphospholipid syndrome includes elevation of either the lupus anticoagulant titer or the anticardiolipin antibody titer on two occasions, separated by 6 weeks in a patient with an episode of thrombosis."

Elevated anticardiolipin antibody titer is a criterion for diagnosing antiphospholipid syndrome.

Beta-2 Glycoprotein I Antibodies (Positive)

Show evidence (4 references)

PMID:7795615 SUPPORT Human Clinical

"Anticardiolipin (aCL) and anti-beta 2-glycoprotein I(anti beta 2GPI) antibodies have been shown in animal models as not cross-reacting antibody populations."

The abstract mentions the detection and study of anti-beta 2GPI antibodies, indicating their presence.

PMID:25292011 SUPPORT Human Clinical

"abeta2 Gp1 (anti-betaeta-2 glycoprotein 1) antibody and LAC (lupus anticoagulant) of 1222 consecutive patients referred to the coagulation laboratory work-up for a hypercoagulable/thrombophilic state."

The study evaluates the frequency of APS including the presence of anti-beta 2 glycoprotein 1 antibodies, supporting their association with the syndrome.

PMID:21046294 SUPPORT Human Clinical

"Although many antigens have been identified in relation to the antiphospholipid syndrome, beta2-glycoprotein I is regarded as clinically most significant."

The connection between beta2-glycoprotein I antibodies and APS is clearly established in the context of the syndrome.

+ 1 more reference

Anti-Smith Antibodies (Negative)

Show evidence (1 reference)

PMID:24420722 SUPPORT Human Clinical

"anti-Smith (Sm) antibodies were not detected in both groups."

The study indicates that anti-Smith antibodies were not detected in the APS/SLE group, confirming that anti-Smith antibodies are negative in patients with APS.

🔀

Differential Diagnoses

3

Conditions with similar clinical presentations that must be differentiated from Antiphospholipid Syndrome:

Thrombotic thrombocytopenic purpura Not Yet Curated MONDO:0018896

Overlapping Features Thrombotic thrombocytopenic purpura can closely mimic catastrophic APS through thrombocytopenia, microangiopathic hemolysis, neurologic injury, renal dysfunction, and multiorgan ischemia.

Distinguishing Features

Undetectable ADAMTS13 activity strongly favors thrombotic thrombocytopenic purpura.
Persistent antiphospholipid antibodies and the need for anticoagulation favor catastrophic APS over TTP.

Show evidence (2 references)

PMID:10483019 SUPPORT Human Clinical

"The differential diagnosis of CAPS includes thrombotic thrombocytopenic purpura (TTP) and this distinction may be difficult, but essential, for appropriate therapy."

This directly identifies TTP as a core differential diagnosis for catastrophic APS.

PMID:25879992 SUPPORT Human Clinical

"The definitive marker for thrombotic thrombocytopenic purpura is undetectable ADAMTS 13 activity."

This supports ADAMTS13 deficiency as a key laboratory feature distinguishing TTP from APS-related thrombotic microangiopathy.

HELLP syndrome Not Yet Curated MONDO:0008585

Overlapping Features HELLP syndrome overlaps with obstetric APS and catastrophic APS through thrombocytopenia, hemolysis, liver injury, and severe pregnancy-associated maternal morbidity.

Distinguishing Features

A pregnancy-specific pre-eclampsia context with hemolysis, elevated liver enzymes, and low platelet count favors HELLP syndrome.
Neurologic involvement, dialysis requirement, or absent disseminated intravascular coagulation raise concern for thrombotic microangiopathy or APS mimics rather than isolated HELLP.

Show evidence (2 references)

PMID:25879992 SUPPORT Human Clinical

"Pre-eclampsia complicated by severe HELLP (hemolysis, elevated liver enzymes and low platelet count) syndrome is a multi-organ disease, and can be difficult to differentiate from thrombotic microangiopathy (appearing as thrombotic thrombocytopenic purpura or hemolytic uremic syndrome), acute..."

This review explicitly names antiphospholipid syndrome among the major disorders that can be confused with severe HELLP syndrome.

PMID:25879992 SUPPORT Human Clinical

"Relevant identifiers to establish the most accurate diagnosis include the frequency of each disease and anamnestic data. Frank hemolysis, need for dialysis, neurological involvement and absence of disseminated intravascular coagulation are indicative of thrombotic microangiopathy."

This supports specific distinguishing features that help separate HELLP syndrome from APS-related thrombotic microangiopathy.

Systemic lupus erythematosus MONDO:0007915

Overlapping Features Systemic lupus erythematosus frequently co-occurs with APS and may be mistaken for primary APS when antiphospholipid antibodies are present alongside broader systemic autoimmune findings.

Distinguishing Features

SLE-specific nephropathy, arthritis, cutaneous or neurologic lupus manifestations, anti-dsDNA, anti-Sm, or high-titer ANA favor systemic lupus erythematosus.
Strictly defined primary APS can satisfy some lupus classification items without progressing to clinical SLE on long-term follow-up.

Show evidence (2 references)

PMID:30005859 SUPPORT Human Clinical

"We successively excluded patients with (1) at least one "SLE-specific" manifestation (biopsy-proven SLE nephropathy, arthritis, cutaneous, or neurologic SLE manifestations, pericarditis, autoimmune haemolytic anaemia, oral and nasal ulcers, non-scarring alopecia, anti-dsDNA, and anti-Sm..."

This cohort analysis outlines the clinical and serologic features used to distinguish SLE from primary APS.

PMID:30005859 SUPPORT Human Clinical

"Because 28% of our patients with longstanding and strictly defined PAPS could be mistakenly classified as SLE, they were at risk of deleterious therapeutic management."

This directly supports SLE as an important diagnostic pitfall and differential diagnosis for primary APS.

📊

Related Datasets

3

A Genome-Wide Association Study Suggests New Susceptibility Loci for Primary Antiphospholipid Syndrome DOI:10.1002/art.42947

Large genome-wide association study resource for primary APS, used to identify susceptibility loci and compare the genetic architecture of APS with other immune-mediated diseases.

human GWAS n=5485

Conditions: primary antiphospholipid syndrome immune-mediated disease genetic comparison

PMID:38973605

Show evidence (1 reference)

PMID:38973605 SUPPORT Human Clinical

"METHODS: We performed a genome-wide association study comprising 5,485 individuals (482 affected individuals) of European ancestry."

This supports the cohort size and GWAS design of a major primary APS genetics dataset.

Gene profiling reveals specific molecular pathways in the pathogenesis of atherosclerosis and cardiovascular disease in antiphospholipid syndrome, systemic lupus erythematosus and antiphospholipid syndrome with lupus DOI:10.1136/annrheumdis-2013-204600

Human monocyte microarray dataset comparing APS, APS plus SLE, SLE, and healthy donors to define inflammatory, atherosclerotic, and prothrombotic transcriptional programs.

human MICROARRAY n=190

peripheral blood monocytes link

Conditions: primary antiphospholipid syndrome antiphospholipid syndrome associated with systemic lupus erythematosus systemic lupus erythematosus healthy controls

PMID:24618261

Show evidence (1 reference)

PMID:24618261 SUPPORT Human Clinical

"METHODS: 129 patients (42 APS, 31 APS plus SLE and 56 SLE) and 61 healthy donors were included. Microarray expression profiling was performed in monocytes."

This supports a disease-relevant monocyte transcriptomic dataset spanning APS and overlapping autoimmune comparator groups.

Urine Proteomics Differentiate Primary Thrombotic Antiphospholipid Syndrome From Obstetric Antiphospholipid Syndrome DOI:10.3389/fimmu.2021.702425

Urine proteomics dataset distinguishing primary thrombotic APS from primary obstetric APS using iTRAQ and liquid chromatography-tandem mass spectrometry.

human PROTEOMICS n=39

urine sample

Conditions: primary thrombotic antiphospholipid syndrome primary obstetric antiphospholipid syndrome healthy controls

PMID:34489952

Show evidence (1 reference)

PMID:34489952 SUPPORT Human Clinical

"Urine samples from 15 patients with TAPS, 9 patients with OAPS, and 15 healthy controls (HCs) were collected and analyzed using isobaric tags for relative and absolute quantification (iTRAQ) labeling combined with liquid chromatography-tandem mass spectrometry analysis to identify differentially..."

This supports a human APS proteomics dataset spanning thrombotic and obstetric primary APS subgroups.

🔬

Clinical Trials

4

NCT05199909 PHASE_II RECRUITING

Single-arm phase II study evaluating zanubrutinib for antiphospholipid syndrome with secondary thrombocytopenia.

Target Phenotypes: Thrombocytopenia ↗

Show evidence (1 reference)

clinicaltrials:NCT05199909 SUPPORT Human Clinical

"To evaluate the safety and efficacy of zanubrutinib in the treatment of antiphospholipid syndrome with secondary thrombocytopenia in 10 patients."

This supports the study objective, intervention, and thrombocytopenia-focused APS population.

NCT05671757 PHASE_I RECRUITING

Dose-escalation safety trial of daratumumab in primary APS, designed to define tolerated dosing and early safety.

Show evidence (2 references)

clinicaltrials:NCT05671757 SUPPORT Human Clinical

"The purpose of this study is to see if the study medication, daratumumab, is safe to treat individuals with Anti-Phospholipid Syndrome (APS)."

This supports daratumumab as an actively recruiting investigational therapy for primary APS.

clinicaltrials:NCT05671757 SUPPORT Human Clinical

"The primary objective is to determine the safety of daratumumab in APS defined as Dose Limiting Toxicities (DLTs) occurring during the dose escalation phase."

This supports representing the combined Phase 1/2 study as a phase I-style dose-escalation safety trial in schema-constrained form.

NCT02157272 PHASE_III TERMINATED

Randomized trial comparing rivaroxaban versus warfarin in high-risk triple-positive thrombotic APS.

Target Phenotypes: Deep Vein Thrombosis ↗ Stroke ↗

Show evidence (1 reference)

clinicaltrials:NCT02157272 SUPPORT Human Clinical

"Primary Study Objective(s) The primary objective is to demonstrate the non-inferiority of Rivaroxaban 20 mg (or 15mgqd in case of moderate renal insufficiency) versus warfarin (INR 2.0-3.0) with respect to the occurrence of the cumulative end point of incident acute thrombosis (arterial or..."

This supports the anticoagulation comparison, high-risk APS population, and thrombotic endpoints addressed by the trial.

NCT04275778 PHASE_II UNKNOWN

Phase II obstetric APS trial evaluating adjunct hydroxychloroquine with conventional aspirin and low-molecular-weight heparin management to improve uncomplicated term pregnancy.

Target Phenotypes: Preterm Birth ↗ Preeclampsia ↗

Show evidence (1 reference)

clinicaltrials:NCT04275778 SUPPORT Human Clinical

"The objective of this clinical trial is to evaluate the benefit of addition or no of hydroxychloroquine to conventional treatment in obstetric APS."

This supports an interventional obstetric APS trial testing hydroxychloroquine as adjunct therapy.

📚

Literature Summaries

2

Disorder ▸

Disorder

Name: Antiphospholipid Syndrome
Category: Complex
Existing deep-research providers: falcon
Existing evidence reference count in YAML: 99

Key Pathophysiology Nodes

Antibody Production
Blood Clot Formation
Impaired Blood Flow
Organ Damage
Pregnancy Complications
Chronic Complications
Deep research literature mapping

Citation Inventory (for evidence mapping)

DOI:10.1093/rheumatology/kead575
DOI:10.1093/rheumatology/keae397
DOI:10.1111/bjh.19635
DOI:10.3389/fimmu.2025.1639065
DOI:10.3389/fimmu.2025.1676578
DOI:10.3390/cells14050353
DOI:10.3390/ijms24043195
DOI:10.3390/jcm13144191
DOI:10.7759/cureus.66555

Falcon ▸

Disease Pathophysiology Research Report

Edison Scientific Literature 28 citations 2025-12-03T22:20:58.523511

Disease Pathophysiology Research Report

Target Disease - Disease Name: Antiphospholipid Syndrome (APS) - MONDO ID: not definitively assigned here - Category: Complex, autoimmune thrombo-inflammatory disease

Pathophysiology description - Core paradigm. APS is driven by antiphospholipid antibodies (aPL) that recognize phospholipid-binding proteins—most notably β2-glycoprotein I (β2GPI)—on vascular and placental cells, shifting hemostasis toward a prothrombotic and proinflammatory state. Anti-β2GPI (especially domain I-directed) and anti-cardiolipin antibodies, with lupus anticoagulant positivity, are necessary but insufficient; a “second hit” (e.g., infection, pregnancy, surgery) frequently precipitates clinically overt thrombosis or obstetric morbidity (two-hit model) (10.1111/bjh.19635, Jul 2024; 10.7759/cureus.66555, Aug 2024) (arachchillage2024guidelinesonthe pages 2-2, parepalli2024antiphospholipidsyndromeand pages 2-3). - aPL–β2GPI interactions and coagulation. Anti-β2GPI binds β2GPI on endothelial cells, monocytes, and platelets, inducing tissue factor (TF) expression and impairing anticoagulant/fibrinolytic balances (protein C/TFPI suppression; increased PAI-1), thereby enhancing thrombin generation and clot persistence (10.3390/jcm13144191, Jul 2024; 10.3389/fimmu.2025.1639065, Aug 2025; 10.3390/cells14050353, Feb 2025) (celia2024antiphospholipidsyndromeinsights pages 3-5, zhu2025noveladvanceson pages 3-4, bucci2025statinsasan pages 2-4). - Platelet and endothelial activation. aPL–β2GPI complexes activate platelets via ApoER2, GPIbα and αIIbβ3, triggering p38/PI3K–AKT signaling, ROS/TXA2 generation, and aggregation; endothelial cells upregulate NF-κB–dependent adhesion molecules (E-selectin/VCAM-1/ICAM-1), cytokines (IL-6/IL-8), and TF, reflecting a prothrombo-inflammatory transcriptomic program (10.3390/cells14050353; 10.1093/rheumatology/kead575, Feb 2024; 10.3390/jcm13144191) (bucci2025statinsasan pages 2-4, lopezpedrera2024newadvancesin pages 1-2, celia2024antiphospholipidsyndromeinsights pages 3-5). - Complement and NETs. Complement activation integrates with coagulation and cell activation. In APS kidney tissue, RNA-seq shows strong upregulation of C3/C4A/C4B and enrichment for type I IFN signaling; NET-related genes are also upregulated, implicating immunothrombosis at the organ level (10.1093/rheumatology/keae397, Aug 2024) (tektonidou2024kidneywholetranscriptomeprofiling pages 4-6). Guidelines emphasize complement and NETs as important pathomechanisms, with CAPS representing an extreme thromboinflammatory state often precipitated by triggers (10.1111/bjh.19635) (arachchillage2024guidelinesonthe pages 2-2). - Interferon/TLR axis. Multiple independent transcriptomic datasets show type I interferon-regulated genes (e.g., IFI6, IFI44, MX1, OAS1, RSAD2) are upregulated across APS, with links to thrombosis and preeclampsia; “a distinct signature comprising 11 IFN-induced genes” was reported in PBMCs (10.1093/rheumatology/kead575) (lopezpedrera2024newadvancesin pages 4-5). Anti-β2GPI signaling engages TLR4 (and TLR7/8) to activate p38/MEK/ERK and NF-κB, upregulating TF and adhesion molecules (10.3389/fimmu.2025.1639065) (zhu2025noveladvanceson pages 3-4). - Obstetric APS (OAPS) mechanisms. Beyond thrombosis, aPL directly perturb placental biology: trophoblast dysfunction, loss of annexin V shield, altered angiogenic signaling, and immune dysregulation contribute to placental insufficiency, fetal growth restriction, preeclampsia, and pregnancy loss; aPS/PT associates with obstetric complications (10.3390/ijms24043195, Feb 2023) (d’ippolito2023antiphospholipidsyndromein pages 4-5). Placental and endothelial inflammation signatures converge (IL-6/IL-8/selectins/ICAM/VCAM/TGF-β2) (10.1093/rheumatology/kead575) (lopezpedrera2024newadvancesin pages 1-2). - Systems immunothrombosis. Unbiased proteomics in aPL-positive individuals reveals a graded thromboinflammatory signature across clinical phenotypes—activation of coagulation, complement, neutrophil pathways, and ECM organization—increasing from aPL carriers to thrombotic and microvascular APS (10.3389/fimmu.2025.1676578, Oct 2025) (pine2025aproteomicmap pages 1-2).

Recent developments and latest research (priority 2023–2024) - Kidney transcriptomics (2024): Upregulated C3/C4A/C4B (logFC ~2.1–2.3) and IFN-α/β signaling; NETs-related genes increased in APS kidney biopsies, mirroring prior whole-blood signatures (10.1093/rheumatology/keae397, Aug 2024) (tektonidou2024kidneywholetranscriptomeprofiling pages 4-6). - IFN signatures (2024): “Upregulation of IFN-related genes in patients with APS” consistent across whole blood, PBMCs and neutrophils; an 11-gene IFN panel distinguished APS from controls (10.1093/rheumatology/kead575, Feb 2024) (lopezpedrera2024newadvancesin pages 4-5). - Endothelial gene programs (2024): aPL/β2GPI induce endothelial NF-κB/MAPK/TGF-β activation with IL-6/IL-8 and adhesion molecule upregulation; similar activation detected in APS placental tissue (10.1093/rheumatology/kead575) (lopezpedrera2024newadvancesin pages 1-2). - Guidelines synthesis (2024): APS hypercoagulability arises from cell activation (endothelium/monocyte/platelet/neutrophil), complement and NETs, with two-hit triggers; management emphasizes vitamin K antagonists (VKA) for thrombotic APS and individualized therapy (10.1111/bjh.19635, Jul 2024) (arachchillage2024guidelinesonthe pages 2-2).

Current applications and real-world implementations - Antithrombotic therapy. For thrombotic APS, long-term anticoagulation with VKA is standard; aspirin may be added in selected arterial/refractory cases; LMWH/heparin is used peri-procedurally and in pregnancy (10.1111/bjh.19635) (arachchillage2024guidelinesonthe pages 2-2). - Obstetric APS care. Low-dose aspirin plus LMWH is standard of care; mechanistic understanding of placental inflammation and angiogenic imbalance informs adjunctive strategies (10.3390/ijms24043195) (d’ippolito2023antiphospholipidsyndromein pages 4-5). - Targeted adjuncts. Hydroxychloroquine (HCQ) and statins are considered adjuncts in selected patients (statins: antithrombotic pleiotropy impacting platelet signaling and endothelial inflammation) (10.1111/bjh.19635; 10.3390/cells14050353, Feb 2025) (arachchillage2024guidelinesonthe pages 2-2, bucci2025statinsasan pages 2-4). Complement inhibition (e.g., eculizumab) is employed in refractory situations such as CAPS per expert guidance (10.1111/bjh.19635) (arachchillage2024guidelinesonthe pages 2-2).

Expert opinions and analysis (authoritative sources) - British Journal of Haematology guidelines (2024) synthesize that aPL positivity is “necessary but insufficient,” emphasizing complement, NETs, and a two-hit pathogenesis; VKA remains mainstay for thrombotic APS (10.1111/bjh.19635) (arachchillage2024guidelinesonthe pages 2-2). - Systems-level omics reinforce immunothrombosis: proteomics and RNA-seq document complement, IFN, and neutrophil/NET pathways in APS tissues and blood (10.1093/rheumatology/keae397; 10.3389/fimmu.2025.1676578) (tektonidou2024kidneywholetranscriptomeprofiling pages 4-6, pine2025aproteomicmap pages 1-2).

Relevant statistics and data from recent studies - APS kidney RNA-seq: C3 (logFC 2.25, P=1.58×10−5), C4A (2.17, P=2.69×10−6), C4B (2.135, P=3.7×10−6) upregulated; nine IFN-regulated genes up in APS vs. controls; 13/15 NETs-related genes higher in APS (10.1093/rheumatology/keae397, Aug 2024) (tektonidou2024kidneywholetranscriptomeprofiling pages 4-6). - IFN signature panels: an 11 IFN-induced gene set (e.g., IFI6/IFI44/RSAD2/MX1) distinguished APS from controls; IFN signatures associated with thrombosis and preeclampsia (10.1093/rheumatology/kead575, Feb 2024) (lopezpedrera2024newadvancesin pages 4-5).

Key concepts and definitions (current understanding) - aPL: Autoantibodies (lupus anticoagulant, anti-cardiolipin IgG/IgM, anti-β2GPI IgG/IgM) that target phospholipid-binding proteins, especially β2GPI; domain I specificity is highly disease-associated (10.3389/fimmu.2025.1639065) (zhu2025noveladvanceson pages 3-4). - Two-hit hypothesis: aPL provide a prothrombotic priming state; inflammation or vascular stress acts as a second hit precipitating overt thrombosis/CAPS (10.1111/bjh.19635; 10.7759/cureus.66555) (arachchillage2024guidelinesonthe pages 2-2, parepalli2024antiphospholipidsyndromeand pages 2-3). - Immunothrombosis: Integration of coagulation, complement, platelets, neutrophils/NETs, and interferon pathways driving thrombosis and microvascular injury (10.1093/rheumatology/keae397; 10.3389/fimmu.2025.1676578) (tektonidou2024kidneywholetranscriptomeprofiling pages 4-6, pine2025aproteomicmap pages 1-2).

Evidence table | Mechanistic theme | Key finding | Biological level | Notable players | Source (journal, year) | URL/DOI | |---|---|---|---|---:|---:| | aPL–β2GPI (domain I) & TF upregulation | "Anti-β2GPI (domain I) binds exposed epitope and induces tissue factor (TF) upregulation in monocytes and endothelial cells" | Molecular / cellular | β2GPI (Domain I), anti‑β2GPI (DI), TF (F3), monocytes, endothelial cells | Frontiers in Immunology (2025); Journal of Clinical Medicine (2024) (zhu2025noveladvanceson pages 3-4, celia2024antiphospholipidsyndromeinsights pages 3-5) | 10.3389/fimmu.2025.1639065; 10.3390/jcm13144191 | | Platelet activation pathways | aβ2GPI/β2GPI complexes engage ApoER2, GPIbα and αIIbβ3 → p38/PI3K‑AKT activation, ROS and TXA2 production → platelet aggregation | Cellular | Platelets, ApoER2, GPIbα, αIIbβ3, p38 MAPK, NADPH oxidase | Cells (2025); Frontiers in Immunology (2025) (bucci2025statinsasan pages 2-4, zhu2025noveladvanceson pages 3-4) | 10.3390/cells14050353; 10.3389/fimmu.2025.1639065 | | Endothelial activation gene programs | Endothelial transcriptomes show NF‑κB–driven upregulation of IL‑6, IL‑8, E‑selectin, VCAM‑1, ICAM‑1 and MAPK/TGFβ pathway activation after aPL/β2GPI exposure | Cellular / organ | Endothelial cells, NF‑κB, IL6, IL8, VCAM1, ICAM1, MAPK | Rheumatology (2024); Journal of Clinical Medicine (2024) (lopezpedrera2024newadvancesin pages 1-2, celia2024antiphospholipidsyndromeinsights pages 3-5) | 10.1093/rheumatology/kead575; 10.3390/jcm13144191 | | Complement activation (biomarkers & pathways) | Upregulation/consumption of complement (C3, C4A, C4B) in APS target tissue; complement split products (C3a/C4a) consistent with activation/consumption | Molecular / organ | C3, C4A, C4B, C5a, terminal complement (C5b‑9) | Rheumatology (kidney RNA‑seq, 2024); British Journal of Haematology guidelines (2024) (tektonidou2024kidneywholetranscriptomeprofiling pages 4-6, arachchillage2024guidelinesonthe pages 2-2) | 10.1093/rheumatology/keae397; 10.1111/bjh.19635 | | NETs signatures / quantitation | NETs‑related genes (MPO, ELANE, PADI4) and NETosis signatures are increased in APS blood and kidney samples | Molecular / cellular | Neutrophils, MPO, ELANE, PADI4, extracellular histones | Rheumatology (kidney RNA‑seq, 2024); Frontiers in Immunology review (2025) (tektonidou2024kidneywholetranscriptomeprofiling pages 4-6, zhu2025noveladvanceson pages 1-3) | 10.1093/rheumatology/keae397; 10.3389/fimmu.2025.1639065 | | Type I interferon transcriptomic signatures (blood & kidney) | "Type I IFN‑regulated genes (IFI6, IFI44, MX1, OAS1) are upregulated across the APS spectrum" (blood and kidney transcriptomes) | Molecular / cellular | IFI6, IFI44, IFI44L, MX1, OAS1, RSAD2 | Rheumatology (IFN signatures, 2024); Rheumatology kidney transcriptome (2024) (lopezpedrera2024newadvancesin pages 5-6, tektonidou2024kidneywholetranscriptomeprofiling pages 4-6) | 10.1093/rheumatology/kead575; 10.1093/rheumatology/keae397 | | Obstetric APS — placental lesions & mechanisms | Placental findings: infarction, decidual vasculopathy, ↑ syncytial knots, ↓ vasculosyncytial membranes; trophoblast dysfunction, altered uNK cell function and angiogenesis | Tissue / organ | Trophoblasts, uterine NK cells, spiral arteries, sFlt‑1/PlGF imbalance | Int J Mol Sci (2023); Rheumatology (2024) (d’ippolito2023antiphospholipidsyndromein pages 4-5, lopezpedrera2024newadvancesin pages 1-2) | 10.3390/ijms24043195; 10.1093/rheumatology/kead575 | | Two‑hit hypothesis (triggers) | aPL constitute a "first hit" creating prothrombotic milieu; infection, pregnancy, surgery, or endothelial injury act as a "second hit" precipitating thrombosis/CAPS | Systemic / clinical | aPLs, infections (e.g., viral), pregnancy, endothelial injury | Cureus review (2024); BJH guidelines (2024) (parepalli2024antiphospholipidsyndromeand pages 2-3, arachchillage2024guidelinesonthe pages 2-2) | 10.7759/cureus.66555; 10.1111/bjh.19635 | | Platelet–complement crosstalk | Platelet activation correlates with lectin pathway proteins and C3dg; platelet–complement interactions modulate thromboinflammatory responses | Cellular / molecular | Platelets, MASP‑2, lectin pathway proteins, C3dg, C3 | Cells/Rheumatology summaries and guidelines (2023–2024) (bucci2025statinsasan pages 2-4, arachchillage2024guidelinesonthe pages 2-2) | 10.3390/cells14050353; 10.1111/bjh.19635 | | Biomarkers — anti‑β2GPI‑DI, aPS/PT, triple positivity | Anti‑β2GPI‑domain I shows high specificity for APS; aPS/PT associates with obstetric loss; triple/double aPL positivity increases thrombotic/obstetric risk | Clinical / molecular | anti‑β2GPI‑DI, aPS/PT, LA, aCL (IgG/IgM) | Front Immunol / J Clin Med summaries (2025, 2024) (zhu2025noveladvanceson pages 3-4, celia2024antiphospholipidsyndromeinsights pages 3-5) | 10.3389/fimmu.2025.1639065; 10.3390/jcm13144191 | | Therapeutic implications / targets | Standard: anticoagulation (LMWH/heparin, VKA) ± aspirin; adjuncts with HCQ, statins; complement inhibitors (eculizumab) for refractory/CAPS cases | Clinical | Heparin/LMWH, VKA, aspirin, hydroxychloroquine, statins, eculizumab | BJH guidelines (2024); Cells (statins review, 2025) (arachchillage2024guidelinesonthe pages 2-2, bucci2025statinsasan pages 2-4) | 10.1111/bjh.19635; 10.3390/cells14050353 |

Table: Concise, sourced evidence summarizing key mechanistic themes in antiphospholipid syndrome (APS), with biological level, primary players, and citations to the supporting literature (context IDs). This table is designed for rapid knowledge‑base ingestion and mechanistic mapping.

Key Molecular Players and Ontology-aligned annotations - Genes/Proteins (HGNC): APOER2/LRP8; GP1BA; ITGA2B/ITGB3; F3 (Tissue factor); TFPI; SERPINE1 (PAI-1); PROS1 (Protein S); C3, C4A, C4B; IFI6, IFI44, MX1, OAS1, RSAD2; MPO, ELANE, PADI4; VCAM1, ICAM1, SELE; NFKB1 (bucci2025statinsasan pages 2-4, zhu2025noveladvanceson pages 3-4, tektonidou2024kidneywholetranscriptomeprofiling pages 4-6, lopezpedrera2024newadvancesin pages 1-2, lopezpedrera2024newadvancesin pages 4-5). - Chemical entities (CHEBI): Thromboxane A2; Prostacyclin; Reactive oxygen species; Heparin; Warfarin; Acetylsalicylic acid (aspirin) (bucci2025statinsasan pages 2-4, arachchillage2024guidelinesonthe pages 2-2). - Cell types (CL): Platelet; Endothelial cell; Monocyte; Neutrophil; Trophoblast; Uterine NK cell (bucci2025statinsasan pages 2-4, d’ippolito2023antiphospholipidsyndromein pages 4-5, lopezpedrera2024newadvancesin pages 1-2). - Anatomical locations (UBERON): Blood vessel endothelium; Placenta; Kidney (nephron); Decidua; Spiral artery (tektonidou2024kidneywholetranscriptomeprofiling pages 4-6, d’ippolito2023antiphospholipidsyndromein pages 4-5, lopezpedrera2024newadvancesin pages 1-2). - Biomarkers: anti-β2GPI (domain I); lupus anticoagulant; anti-cardiolipin; anti-phosphatidylserine/prothrombin (aPS/PT); complement split products (C3a/C4a); IFN gene signature panels (zhu2025noveladvanceson pages 3-4, d’ippolito2023antiphospholipidsyndromein pages 4-5, celia2024antiphospholipidsyndromeinsights pages 3-5, lopezpedrera2024newadvancesin pages 4-5).

Biological Processes (GO-style terms) disrupted - Blood coagulation and regulation of thrombin generation; extrinsic coagulation via tissue factor; fibrinolysis and regulation of plasminogen activation (bucci2025statinsasan pages 2-4, celia2024antiphospholipidsyndromeinsights pages 3-5). - Complement activation (classical/lectin/alternative collectively implicated by C3/C4 upregulation and C3a/C4a split products) (tektonidou2024kidneywholetranscriptomeprofiling pages 4-6, celia2024antiphospholipidsyndromeinsights pages 3-5). - Neutrophil activation and neutrophil extracellular trap formation (NETosis) (tektonidou2024kidneywholetranscriptomeprofiling pages 4-6, arachchillage2024guidelinesonthe pages 2-2). - Type I interferon signaling; innate immune activation; TLR signaling pathways (TLR4/TLR7/8) (lopezpedrera2024newadvancesin pages 4-5, zhu2025noveladvanceson pages 3-4). - Endothelial activation: NF-κB signaling, cytokine production (IL-6/IL-8), cell adhesion (VCAM-1/ICAM-1/E-selectin) (lopezpedrera2024newadvancesin pages 1-2). - Placental development and angiogenesis; trophoblast differentiation and invasion; decidual vasculature remodeling (d’ippolito2023antiphospholipidsyndromein pages 4-5, lopezpedrera2024newadvancesin pages 1-2).

Cellular Components implicated - Plasma membrane complexes (β2GPI–aPL complexes on endothelial cells, platelets, monocytes); lipid rafts; integrin αIIbβ3 (bucci2025statinsasan pages 2-4, celia2024antiphospholipidsyndromeinsights pages 3-5). - Extracellular space: NETs (DNA–histone complexes with MPO/ELANE), complement components (C3, C4), and thrombin/fibrin (tektonidou2024kidneywholetranscriptomeprofiling pages 4-6, arachchillage2024guidelinesonthe pages 2-2). - Endothelial Weibel–Palade bodies/adhesion molecule-rich surfaces; platelet granules (lopezpedrera2024newadvancesin pages 1-2, bucci2025statinsasan pages 2-4).

Disease progression: sequence of events - Initiation: Persistent aPL (often triple-positive) bind β2GPI/prothrombin on cell surfaces; endothelial cells, monocytes, platelets are primed; IFN/TLR pathways heighten inflammatory tone (zhu2025noveladvanceson pages 3-4, lopezpedrera2024newadvancesin pages 4-5). - Trigger (“second hit”): Infection, surgery, pregnancy, or vascular injury causes overt cell activation, TF exposure, complement amplification, and NETosis (arachchillage2024guidelinesonthe pages 2-2, parepalli2024antiphospholipidsyndromeand pages 2-3). - Thromboinflammation: Thrombin generation increases; platelets aggregate (ApoER2/GPIbα/αIIbβ3; PI3K–AKT, p38); endothelium upregulates adhesion molecules and cytokines; complement split products (C3a/C5a) amplify (bucci2025statinsasan pages 2-4, lopezpedrera2024newadvancesin pages 1-2, tektonidou2024kidneywholetranscriptomeprofiling pages 4-6). - Clinical manifestation: Macrovascular thrombosis (venous/arterial) or microvascular occlusion (e.g., APS nephropathy); obstetric morbidity via placental dysfunction and insufficiency (arachchillage2024guidelinesonthe pages 2-2, tektonidou2024kidneywholetranscriptomeprofiling pages 4-6, d’ippolito2023antiphospholipidsyndromein pages 4-5). - Severe phenotype: Catastrophic APS with disseminated microvascular thromboses, often following a strong trigger and with complement involvement (arachchillage2024guidelinesonthe pages 2-2).

Phenotypic manifestations and mechanistic links - Thrombosis (HP:0001907 venous; HP:0005110 arterial): TF-driven thrombin generation, platelet hyperreactivity, NETs and complement amplification (bucci2025statinsasan pages 2-4, arachchillage2024guidelinesonthe pages 2-2, tektonidou2024kidneywholetranscriptomeprofiling pages 4-6). - Obstetric complications: Recurrent pregnancy loss (HP:0005268), preeclampsia (HP:0002372), fetal growth restriction (HP:0001511), placental insufficiency (HP:0001987) due to trophoblast dysfunction, decidual vasculopathy, and placental inflammation (10.3390/ijms24043195; 10.1093/rheumatology/kead575) (d’ippolito2023antiphospholipidsyndromein pages 4-5, lopezpedrera2024newadvancesin pages 1-2). - APS nephropathy (HP:0033411 microangiopathy): Complement/IFN/NETs-related transcriptional programs in kidney (10.1093/rheumatology/keae397) (tektonidou2024kidneywholetranscriptomeprofiling pages 4-6). - CAPS: Multiorgan microvascular thromboses with high mortality; driven by aPL with strong second hits and complement activation (10.1111/bjh.19635) (arachchillage2024guidelinesonthe pages 2-2).

Direct quotes supporting key statements - “Interferon (IFN) alpha/beta signalling was revealed by Reactome” in APS kidney transcriptomes; complement genes C3/C4A/C4B were upregulated (10.1093/rheumatology/keae397, Aug 2024) (tektonidou2024kidneywholetranscriptomeprofiling pages 4-6). - “Upregulation of IFN-related genes in patients with APS” was observed across whole blood, PBMCs and neutrophils; a PBMC panel identified “a distinct signature comprising 11 IFN-induced genes” (10.1093/rheumatology/kead575, Feb 2024) (lopezpedrera2024newadvancesin pages 4-5).

Therapeutic implications/targets informed by pathophysiology - Anticoagulation (VKA) remains first-line for thrombotic APS; heparin/LMWH and aspirin applied per risk/setting (10.1111/bjh.19635) (arachchillage2024guidelinesonthe pages 2-2). - Targeting cell activation and inflammation: HCQ as adjunct; statins for selected high-risk thrombotic APS to attenuate platelet/endothelial activation; investigational complement inhibition for refractory/CAPS (10.1111/bjh.19635; 10.3390/cells14050353) (arachchillage2024guidelinesonthe pages 2-2, bucci2025statinsasan pages 2-4).

Evidence items (PMIDs/DOIs/URLs; publication dates) - Arachchillage DJ et al. Guidelines on the investigation and management of antiphospholipid syndrome. British Journal of Haematology. Jul 2024. doi:10.1111/bjh.19635; https://doi.org/10.1111/bjh.19635 (arachchillage2024guidelinesonthe pages 2-2). - Tektonidou MG et al. Kidney whole-transcriptome profiling… Rheumatology (Oxford). Aug 2024. doi:10.1093/rheumatology/keae397; https://doi.org/10.1093/rheumatology/keae397 (tektonidou2024kidneywholetranscriptomeprofiling pages 4-6). - López‑Pedrera C et al. New advances in genomics and epigenetics in APS. Rheumatology. Feb 2024. doi:10.1093/rheumatology/kead575; https://doi.org/10.1093/rheumatology/kead575 (lopezpedrera2024newadvancesin pages 1-2, lopezpedrera2024newadvancesin pages 4-5). - Celia AI et al. Antiphospholipid syndrome: insights… Journal of Clinical Medicine. Jul 2024. doi:10.3390/jcm13144191; https://doi.org/10.3390/jcm13144191 (celia2024antiphospholipidsyndromeinsights pages 3-5). - Zhu Q‑N et al. Novel advances… Frontiers in Immunology. Aug 2025. doi:10.3389/fimmu.2025.1639065; https://doi.org/10.3389/fimmu.2025.1639065 (zhu2025noveladvanceson pages 3-4, zhu2025noveladvanceson pages 1-3). - Bucci T et al. Statins as an adjunctive antithrombotic agent in T‑APS. Cells. Feb 2025. doi:10.3390/cells14050353; https://doi.org/10.3390/cells14050353 (bucci2025statinsasan pages 2-4). - Pine A et al. A proteomic map of thromboinflammatory signatures in APS. Frontiers in Immunology. Oct 2025. doi:10.3389/fimmu.2025.1676578; https://doi.org/10.3389/fimmu.2025.1676578 (pine2025aproteomicmap pages 1-2). - D’Ippolito S et al. APS in pregnancy: pathogenetic mechanisms. Int J Mol Sci. Feb 2023. doi:10.3390/ijms24043195; https://doi.org/10.3390/ijms24043195 (d’ippolito2023antiphospholipidsyndromein pages 4-5).

Note on scope and gaps - Where detailed quantitative NET biomarker cutoffs and specific complement split-product levels in APS cohorts are needed, additional prospective studies are emerging but were beyond the scope of the cited transcripts/guidelines.

References

(arachchillage2024guidelinesonthe pages 2-2): Deepa J. Arachchillage, Sean Platton, Kieron Hickey, Justin Chu, Matthew Pickering, Peter Sommerville, Peter MacCallum, and Karen Breen. Guidelines on the investigation and management of antiphospholipid syndrome. British Journal of Haematology, 205:855-880, Jul 2024. URL: https://doi.org/10.1111/bjh.19635, doi:10.1111/bjh.19635. This article has 39 citations and is from a domain leading peer-reviewed journal.
(parepalli2024antiphospholipidsyndromeand pages 2-3): Avinash Parepalli, Rajesh Sarode, Sunil Kumar, Manikanta Nelakuditi, and M Jayanth Kumar. Antiphospholipid syndrome and catastrophic antiphospholipid syndrome: a comprehensive review of pathogenesis, clinical features, and management strategies. Cureus, Aug 2024. URL: https://doi.org/10.7759/cureus.66555, doi:10.7759/cureus.66555. This article has 10 citations and is from a poor quality or predatory journal.
(celia2024antiphospholipidsyndromeinsights pages 3-5): Alessandra Ida Celia, Mattia Galli, Silvia Mancuso, Cristiano Alessandri, Giacomo Frati, Sebastiano Sciarretta, and Fabrizio Conti. Antiphospholipid syndrome: insights into molecular mechanisms and clinical manifestations. Journal of Clinical Medicine, 13:4191, Jul 2024. URL: https://doi.org/10.3390/jcm13144191, doi:10.3390/jcm13144191. This article has 14 citations and is from a poor quality or predatory journal.
(zhu2025noveladvanceson pages 3-4): Qing-Nan Zhu, Xiang-Bo Qi, Shu-Wei Ren, Yu-Ye Li, Ze-Wen Yan, Yu Sun, Yan Shi, Qing-Si Wen, Mao-Mao Wu, and Da-Peng Wang. Novel advances on pathophysiological mechanisms, clinical manifestations, and treatment of antiphospholipid syndrome. Frontiers in Immunology, Aug 2025. URL: https://doi.org/10.3389/fimmu.2025.1639065, doi:10.3389/fimmu.2025.1639065. This article has 3 citations and is from a peer-reviewed journal.
(bucci2025statinsasan pages 2-4): Tommaso Bucci, Danilo Menichelli, Ilaria Maria Palumbo, Daniele Pastori, Paul R. J. Ames, Gregory Y. H. Lip, and Pasquale Pignatelli. Statins as an adjunctive antithrombotic agent in thrombotic antiphospholipid syndrome: mechanisms and clinical implications. Cells, 14:353, Feb 2025. URL: https://doi.org/10.3390/cells14050353, doi:10.3390/cells14050353. This article has 4 citations and is from a poor quality or predatory journal.
(lopezpedrera2024newadvancesin pages 1-2): Chary López-Pedrera, Tomás Cerdó, Elizabeth C Jury, Laura Muñoz-Barrera, Alejandro Escudero-Contreras, M A Aguirre, and Carlos Pérez-Sánchez. New advances in genomics and epigenetics in antiphospholipid syndrome. Rheumatology, 63:SI14-SI23, Feb 2024. URL: https://doi.org/10.1093/rheumatology/kead575, doi:10.1093/rheumatology/kead575. This article has 8 citations and is from a peer-reviewed journal.
(tektonidou2024kidneywholetranscriptomeprofiling pages 4-6): Maria G Tektonidou, Kleio-Maria Verrou, Harikleia Gakiopoulou, Menelaos Manoloukos, Panagiotis Lembessis, Pantelis Hatzis, and Petros P Sfikakis. Kidney whole-transcriptome profiling in primary antiphospholipid syndrome reveals complement, interferons and nets-related gene expression. Rheumatology (Oxford, England), 63:3184-3190, Aug 2024. URL: https://doi.org/10.1093/rheumatology/keae397, doi:10.1093/rheumatology/keae397. This article has 9 citations.
(lopezpedrera2024newadvancesin pages 4-5): Chary López-Pedrera, Tomás Cerdó, Elizabeth C Jury, Laura Muñoz-Barrera, Alejandro Escudero-Contreras, M A Aguirre, and Carlos Pérez-Sánchez. New advances in genomics and epigenetics in antiphospholipid syndrome. Rheumatology, 63:SI14-SI23, Feb 2024. URL: https://doi.org/10.1093/rheumatology/kead575, doi:10.1093/rheumatology/kead575. This article has 8 citations and is from a peer-reviewed journal.
(d’ippolito2023antiphospholipidsyndromein pages 4-5): Silvia D’Ippolito, Greta Barbaro, Carmela Paciullo, Chiara Tersigni, Giovanni Scambia, and Nicoletta Di Simone. Antiphospholipid syndrome in pregnancy: new and old pathogenetic mechanisms. International Journal of Molecular Sciences, 24:3195, Feb 2023. URL: https://doi.org/10.3390/ijms24043195, doi:10.3390/ijms24043195. This article has 60 citations and is from a poor quality or predatory journal.
(pine2025aproteomicmap pages 1-2): Alexander Pine, Ayesha Butt, Laura Andreoli, Jason S. Knight, Maria Gerosa, Irene Cecchi, D. Ware Branch, Rosario Lopez-Pedrera, H. Michael Belmont, Nina Kello, Michelle Petri, Ricard Cervera, Vittorio Pengo, Pier Luigi Meroni, Hannah Cohen, Rohan Willis, Maria Laura Bertolccini, George Goshua, Sean Gu, John Hwa, Alfred I. Lee, Doruk Erkan, and Anish V. Sharda. A proteomic map of thromboinflammatory signatures in antiphospholipid syndrome: results from antiphospholipid syndrome alliance for clinical trials and international networking (aps action) registry. Frontiers in Immunology, Oct 2025. URL: https://doi.org/10.3389/fimmu.2025.1676578, doi:10.3389/fimmu.2025.1676578. This article has 0 citations and is from a peer-reviewed journal.
(zhu2025noveladvanceson pages 1-3): Qing-Nan Zhu, Xiang-Bo Qi, Shu-Wei Ren, Yu-Ye Li, Ze-Wen Yan, Yu Sun, Yan Shi, Qing-Si Wen, Mao-Mao Wu, and Da-Peng Wang. Novel advances on pathophysiological mechanisms, clinical manifestations, and treatment of antiphospholipid syndrome. Frontiers in Immunology, Aug 2025. URL: https://doi.org/10.3389/fimmu.2025.1639065, doi:10.3389/fimmu.2025.1639065. This article has 3 citations and is from a peer-reviewed journal.
(lopezpedrera2024newadvancesin pages 5-6): Chary López-Pedrera, Tomás Cerdó, Elizabeth C Jury, Laura Muñoz-Barrera, Alejandro Escudero-Contreras, M A Aguirre, and Carlos Pérez-Sánchez. New advances in genomics and epigenetics in antiphospholipid syndrome. Rheumatology, 63:SI14-SI23, Feb 2024. URL: https://doi.org/10.1093/rheumatology/kead575, doi:10.1093/rheumatology/kead575. This article has 8 citations and is from a peer-reviewed journal.

{ }

Source YAML

click to show

name: Antiphospholipid Syndrome
creation_date: '2025-12-04T16:57:31Z'
updated_date: '2026-03-13T14:31:00Z'
synonyms:
- APS
- antiphospholipid antibody syndrome
- Hughes syndrome
description: A systemic autoimmune disorder characterized by the presence of antiphospholipid antibodies that increase the risk of blood clots and other complications.
definitions:
- name: 2006 Sydney classification criteria for definite APS
  definition_type: DIAGNOSTIC_CRITERIA
  description: >-
    Updated international classification criteria for definite APS requiring at
    least one qualifying clinical criterion and one qualifying laboratory
    criterion.
  scope: Adults with suspected thrombotic or obstetric antiphospholipid syndrome
  criteria_sets:
  - name: Clinical criteria
    description: One or more established thrombotic or obstetric APS manifestations, including vascular thrombosis or qualifying pregnancy morbidity.
    minimum_required: 1
    evidence:
    - reference: PMID:24461539
      reference_title: "Diagnosis and classification of the antiphospholipid syndrome."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: At least one clinical (vascular thrombosis or pregnancy morbidity) and one laboratory (anticardiolipin antibodies, lupus anticoagulant or anti-β2-glycoprotein I antibodies) criterion had to be met for the classification of APS.
      explanation: This supports the clinical arm of the Sydney APS criteria.
  - name: Laboratory criteria
    description: Persistent antiphospholipid antibody positivity documented on repeat testing at least 12 weeks apart.
    minimum_required: 1
    evidence:
    - reference: PMID:20848817
      reference_title: "Antiphospholipid antibody syndrome."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: The 2006 International Consensus Statement on an Update of the Classification Criteria for Definite Antiphospholipid Syndrome has increased the time between the two laboratory studies required for diagnosis from 6 to 12 weeks. Antibody to beta2 glycoprotein 1 has been included as a criterion.
      explanation: This supports persistent repeat serology and inclusion of anti-beta2GPI in the laboratory arm of the criteria.
  evidence:
  - reference: PMID:16420554
    reference_title: "International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS)."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: Based on this, we propose amendments to the Sapporo criteria.
    explanation: This consensus statement defines the Sydney update to the APS classification framework.
  - reference: PMID:24461539
    reference_title: "Diagnosis and classification of the antiphospholipid syndrome."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: At least one clinical (vascular thrombosis or pregnancy morbidity) and one laboratory (anticardiolipin antibodies, lupus anticoagulant or anti-β2-glycoprotein I antibodies) criterion had to be met for the classification of APS.
    explanation: This review summarizes the operational structure of the Sydney APS criteria as one clinical plus one laboratory criterion.
category: Complex
parents:
- Autoimmune Disease
has_subtypes:
- name: Primary APS
  description: occurs in the absence of any other related disease
  evidence:
  - reference: PMID:16338214
    reference_title: "Primary antiphospholipid syndrome: a distinct entity?"
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: the condition can exist on its own. APS appears to represent a clinical spectrum, both in terms of APS features and the presence of other autoimmune conditions. The clinical and serological characteristics of 'primary' APS (PAPS) are similar to those of secondary APS, although the clinical features are more commonly recognised in the presence of another autoimmune or inflammatory condition.
    explanation: The passage supports the statement by indicating that APS can exist on its own without other related diseases, defining it as primary APS (PAPS).
  - reference: PMID:27550302
    reference_title: "Kidney disease in primary anti-phospholipid antibody syndrome."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: APS can be isolated (primary APS) or associated with other autoimmune diseases.
    explanation: This snippet reinforces that APS can exist independently as primary APS.
- name: Secondary APS
  description: occurs with other autoimmune diseases, such as systemic lupus erythematosus
  evidence:
  - reference: PMID:11014973
    reference_title: "Antiphospholipid syndrome."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: APS may be associated with another autoimmune disease (secondary APS), particularly systemic lupus erythematosus (SLE).
    explanation: This reference states that APS can occur with other autoimmune diseases, particularly systemic lupus erythematosus, which supports the statement regarding the subtype Secondary APS.
  - reference: PMID:15507265
    reference_title: "Primary, Secondary, Catastrophic Antiphospholipid Syndrome: is there a difference?"
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: Primary utilized when there is no associated disorder, secondary with an associated autoimmune disorder such as systemic lupus erythematosus (SLE).
    explanation: This reference explains that secondary APS is associated with another autoimmune disorder, specifically mentioning systemic lupus erythematosus (SLE), thus supporting the statement.
  - reference: PMID:19593144
    reference_title: "Antiphospholipid syndrome and systemic lupus erythematosus: are they separate entities or just clinical presentations on the same scale?"
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: Although originally described in the context of systemic lupus erythematosus, antiphospholipid syndrome was then recognized as a primary antiphospholipid syndrome without any underlying autoimmune disease in almost half of the cases.
    explanation: This reference provides context for primary APS being without other autoimmune diseases and implies that secondary APS, in contrast, involves other autoimmune disorders such as systemic lupus erythematosus.
  - reference: PMID:35896399
    reference_title: "Systemic lupus erythematosus and secondary antiphospholipid syndrome in native sisters with reduced fertility."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: Systemic lupus erythematosus (SLE) and secondary anti-phospholipid syndrome (APS II) can cause increased morbidity and mortality of the fetus.
    explanation: This article mentions secondary antiphospholipid syndrome in conjunction with systemic lupus erythematosus, supporting the existence of Secondary APS as a subtype of APS.
  - reference: PMID:10866096
    reference_title: "The family history of patients with primary or secondary antiphospholipid syndrome (APS)."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: We retrospectively studied patients with APS and systemic lupus erythematosus (SLE)...39 patients had primary antiphospholipid syndrome (PAPS) and 69 secondary antiphospholipid syndrome (SAPS).
    explanation: This article gives data on secondary APS occurring along with systemic lupus erythematosus, thus supporting the statement about the existence of the Secondary APS subtype.
  - reference: PMID:26939208
    reference_title: "Extended Antiphospholipid Antibodies Screening in Systemic Lupus Erythematosus Patients."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: 'BACKGROUND: The antiphospholipid syndrome (APS) is one of the most encountered autoimmunity in systemic lupus erythematosus (SLE) patients and pathogenesis of these two seems to be intricate'
    explanation: This article states that APS is common in SLE patients, indicating the close relationship between APS and SLE and supporting the subtype of Secondary APS.
- name: Asymptomatic APS
  description: individuals with antiphospholipid antibodies but no clinical symptoms
  evidence:
  - reference: PMID:17145604
    reference_title: "Managing antiphospholipid antibodies and antiphospholipid syndrome in children."
    supports: PARTIAL
    evidence_source: HUMAN_CLINICAL
    snippet: Antiphospholipid antibodies (aPL) and antiphospholipid syndrome (APS) are increasingly being recognized in children. Transient non-pathogenic aPL are often seen after childhood infections, while thrombotic events seem rare in those with true aPL.
    explanation: The reference supports the existence of individuals with antiphospholipid antibodies but no clinical symptoms, which align with the description of Asymptomatic APS.
  - reference: PMID:15290736
    reference_title: "Antiphospholipid syndrome and asymptomatic carriers of antiphospholipid antibody: prospective analysis of 404 individuals."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "METHODS: We prospectively studied 404 individuals, classified in 2 groups: (1) patients with primary or secondary antiphospholipid syndrome (APS, n = 226); and (2) asymptomatic carriers of aPL (n = 178)."
    explanation: This prospective cohort directly documents a large group of asymptomatic antiphospholipid antibody carriers distinct from clinically manifest APS.
- name: Catastrophic APS
  description: rapidly progressive variant with widespread small-vessel thrombosis and acute multi-organ failure
  evidence:
  - reference: PMID:26753212
    reference_title: "[Catastrophic antiphospholipid syndrome]."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: Catastrophic antiphospholipid syndrome is the most dangerous form of the antiphospholipid syndrome, which is characterized by rapid onset of thrombosis in small vessels of many organs and intravascular coagulation, thrombocytopenia and hemolytic anemia.
    explanation: This review defines catastrophic APS as a severe subtype marked by rapid small-vessel thrombosis and multiorgan involvement.
  - reference: PMID:16394638
    reference_title: "[Catastrophic antiphospholipid syndrome: CAPS]."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: In contrast, so called catastrophic antiphospholipid syndrome, CAPS, develops multiple thromboses at microvessels mainly within a few weeks and induces to poor prognosis.
    explanation: This supports catastrophic APS as a distinct, rapidly progressive APS variant with microvascular thrombosis and poor prognosis.
prevalence:
- population: Global
  percentage: 0.05
  notes: Approximate overall APS prevalence estimate; this figure is not specific to primary APS alone.
  evidence:
  - reference: PMID:28262233
    reference_title: "Antiphospholipid syndrome."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: Some estimates indicate that the incidence of the APS is around 5 new cases per 100,000 persons per year and the prevalence around 40-50 cases per 100,000 persons.
    explanation: This review provides a direct overall APS prevalence estimate consistent with a value near 0.05%.
  - reference: PMID:30957430
    reference_title: "The Epidemiology of Antiphospholipid Syndrome: A Population-Based Study."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: Among this cohort in 2000-2015, 33 cases of incident APS, as defined by the Sydney criteria, were identified... The estimated prevalence of APS was 50 (95% CI 42-58) per 100,000 population, and was similar in both sexes.
    explanation: This population-based estimate independently supports an overall APS prevalence of about 0.05%.
- population: General population
  notes: Contemporary prevalence estimates place APS at roughly 40 to 50 cases per 100,000 population.
  evidence:
  - reference: PMID:28262233
    reference_title: "Antiphospholipid syndrome."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: Some estimates indicate that the incidence of the APS is around 5 new cases per 100,000 persons per year and the prevalence around 40-50 cases per 100,000 persons.
    explanation: This review summarizes contemporary APS prevalence estimates in the 40 to 50 per 100,000 range.
- population: Adults
  notes: Population-based annual incidence is approximately 2.1 cases per 100,000 person-years in adults.
  evidence:
  - reference: PMID:30957430
    reference_title: "The Epidemiology of Antiphospholipid Syndrome: A Population-Based Study."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: APS occurred in ~2 persons per 100,000 population per year.
    explanation: This provides a population-based adult annual incidence estimate for APS.
epidemiology:
- name: Sex distribution varies by study setting
  description: Population-based incidence appears similar in women and men, whereas referral cohorts are often female-predominant.
  factors:
  - sex
  evidence:
  - reference: PMID:30957430
    reference_title: "The Epidemiology of Antiphospholipid Syndrome: A Population-Based Study."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: Incidence rates were similar in both sexes.
    explanation: This population-based study supports similar APS incidence by sex.
  - reference: PMID:31951187
    reference_title: "Characterization of the Clinical and Laboratory Features of Primary and Secondary Antiphospholipid Syndrome in a Cohort of Egyptian Patients."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: The cohort consisted of 148 patients, 135 females (91.2%) and 13 males (8.8%).
    explanation: This referral-cohort study illustrates the strong female predominance often seen in clinical APS series.
progression:
- phase: Onset
  subtype: Primary APS
  age_range: 20-50
  evidence:
  - reference: PMID:34634966
    reference_title: "Distinct features of youth-onset primary antiphospholipid syndrome."
    supports: PARTIAL
    evidence_source: HUMAN_CLINICAL
    snippet: 'We subdivided patients into two groups: youth- (15-24 years) and adult-onset (over 24 years) and compared them regarding demographic characteristics, criteria and non-criteria manifestations, cardiovascular risk factors, and aPL status.'
    explanation: The reference supports that primary APS can indeed onset within the specified age range of 20-50, but it does not provide sufficient evidence to conclude that progression specifically occurs within this exact range.
  - reference: PMID:26125104
    reference_title: "Update on the pathogenesis and treatment of the antiphospholipid syndrome."
    supports: NO_EVIDENCE
    evidence_source: HUMAN_CLINICAL
    snippet: Current innovative treatment options include novel oral anticoagulants and the complement inhibitor eculizumab.
    explanation: While discussing treatment options for APS, this reference does not address the specific age range of 20-50 or the progression of primary APS.
diagnosis:
- name: Sydney criteria clinical and laboratory assessment
  description: >-
    APS classification requires a qualifying clinical event together with a
    qualifying antiphospholipid antibody abnormality.
  evidence:
  - reference: PMID:24461539
    reference_title: "Diagnosis and classification of the antiphospholipid syndrome."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: At least one clinical (vascular thrombosis or pregnancy morbidity) and one laboratory (anticardiolipin antibodies, lupus anticoagulant or anti-β2-glycoprotein I antibodies) criterion had to be met for the classification of APS.
    explanation: This review summarizes the core diagnostic/classification logic used for APS assessment.
- name: Antiphospholipid antibody panel testing
  description: >-
    Standard laboratory evaluation includes lupus anticoagulant,
    anticardiolipin antibodies, and anti-beta2 glycoprotein I antibodies.
  evidence:
  - reference: PMID:26307097
    reference_title: "Diagnosis and therapy of antiphospholipid syndrome."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: According to current guidelines, 3 tests (lupus anticoagulant, anticardiolipin, and anti beta2-glycoprotein I antibodies) are officially recommended to assess the presence of antiphospholipid antibodies.
    explanation: This supports the current core antibody panel used in APS diagnosis.
- name: Repeat confirmatory antibody testing
  description: >-
    Persistent laboratory positivity should be confirmed on repeat testing at
    least 12 weeks apart to avoid classifying transient antibodies as APS.
  evidence:
  - reference: PMID:20848817
    reference_title: "Antiphospholipid antibody syndrome."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: The 2006 International Consensus Statement on an Update of the Classification Criteria for Definite Antiphospholipid Syndrome has increased the time between the two laboratory studies required for diagnosis from 6 to 12 weeks.
    explanation: This supports the requirement for persistent serologic positivity on repeat testing separated by at least 12 weeks.
pathophysiology:
- name: Autoantibody generation against beta2GPI and phospholipid complexes
  description: Adaptive immune responses generate antiphospholipid antibodies that bind beta2 glycoprotein I or negatively charged phospholipids.
  cell_types:
  - preferred_term: B cell
    term:
      id: CL:0000236
      label: B cell
  - preferred_term: T cell
    term:
      id: CL:0000084
      label: T cell
  biological_processes:
  - preferred_term: immunoglobulin production
    term:
      id: GO:0002377
      label: immunoglobulin production
  downstream:
  - target: Cell-surface beta2GPI binding
    description: Circulating aPL bind beta2GPI and phospholipid-associated targets on vascular and placental surfaces.
    causal_link_type: DIRECT
    evidence:
    - reference: PMID:29867951
      reference_title: "Cellular and Molecular Mechanisms of Anti-Phospholipid Syndrome."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: Clinically, the binding of antibodies to β2GPI could contribute to pathogenesis by formation of immune complexes or modification of coagulation steps that operate along cell surfaces.
      explanation: This supports the transition from antibody generation to pathogenic beta2GPI binding on cell surfaces.
  evidence:
  - reference: PMID:29867951
    reference_title: "Cellular and Molecular Mechanisms of Anti-Phospholipid Syndrome."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: The primary anti-phospholipid syndrome (APS) is characterized by the production of antibodies that bind the phospholipid-binding protein β2 glycoprotein I (β2GPI) or that directly recognize negatively charged membrane phospholipids in a manner that may contribute to arterial or venous thrombosis.
    explanation: This review defines the initiating APS event as production of antibodies targeting beta2 glycoprotein I or phospholipids.
  - reference: PMID:33722752
    reference_title: "B cells in primary antiphospholipid syndrome: Review and remaining challenges."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: It is now widely accepted that antiphospholipid antibodies (aPL) have direct pathogenic effects and that B cells, notably through aPL production, play a key role in the development of antiphospholipid syndrome (APS).
    explanation: This supports the role of adaptive immune cells, especially B cells, in generating pathogenic antiphospholipid antibodies.
- name: Cell-surface beta2GPI binding
  description: aPL-beta2GPI complexes accumulate on endothelial, monocyte, platelet, and placental surfaces where they can engage pathogenic receptor systems.
  downstream:
  - target: Innate receptor signaling
    description: Surface-bound immune complexes engage receptors such as TLR4 and trigger downstream inflammatory signaling cascades.
    causal_link_type: DIRECT
    evidence:
    - reference: PMID:22055541
      reference_title: "Examining how antiphospholipid antibodies activate intracellular signaling pathways: a systematic review."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: TLR4, p38 MAPK and NFκB are involved in mediating pathogenic effects of aPL on different cell types and may be potential therapeutic targets in antiphospholipid syndrome.
      explanation: This supports the edge from surface beta2GPI binding to receptor-mediated pathogenic signaling.
  evidence:
  - reference: PMID:29867951
    reference_title: "Cellular and Molecular Mechanisms of Anti-Phospholipid Syndrome."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: Clinically, the binding of antibodies to β2GPI could contribute to pathogenesis by formation of immune complexes or modification of coagulation steps that operate along cell surfaces.
    explanation: This supports pathogenic antibody binding along cellular surfaces as a distinct intermediate APS event.
- name: Innate receptor signaling
  description: aPL-beta2GPI complexes activate TLR4-p38 MAPK-NFkB and related intracellular pathways in susceptible target cells.
  downstream:
  - target: Endothelial activation
    description: Intracellular signaling induces a proadhesive and procoagulant endothelial phenotype.
    causal_link_type: DIRECT
    evidence:
    - reference: PMID:20822807
      reference_title: "Antiphospholipid syndrome."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: Antiphospholipid antibodies promote activation of endothelial cells, monocytes, and platelets; and overproduction of tissue factor and thromboxane A2.
      explanation: This supports endothelial activation as a downstream consequence of pathogenic aPL signaling.
  - target: Monocyte tissue factor induction
    description: Signaling in monocytes induces tissue factor expression and amplifies coagulation.
    causal_link_type: DIRECT
    evidence:
    - reference: PMID:20822807
      reference_title: "Antiphospholipid syndrome."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: Antiphospholipid antibodies promote activation of endothelial cells, monocytes, and platelets; and overproduction of tissue factor and thromboxane A2.
      explanation: This supports monocyte activation with tissue factor induction as a discrete prothrombotic mechanism in APS.
  - target: Platelet activation
    description: Signaling promotes platelet activation and thromboxane-driven thrombus propagation.
    causal_link_type: DIRECT
    evidence:
    - reference: PMID:20822807
      reference_title: "Antiphospholipid syndrome."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: Antiphospholipid antibodies promote activation of endothelial cells, monocytes, and platelets; and overproduction of tissue factor and thromboxane A2.
      explanation: This supports platelet activation as a distinct downstream consequence of aPL signaling.
  evidence:
  - reference: PMID:22055541
    reference_title: "Examining how antiphospholipid antibodies activate intracellular signaling pathways: a systematic review."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: Diverse experimental evidence exists implicating the activation of various different cell surface receptors and intracellular pathways by antiphospholipid antibodies (aPL).
    explanation: This review supports a distinct signaling step between antibody binding and overt thrombosis.
  - reference: PMID:22055541
    reference_title: "Examining how antiphospholipid antibodies activate intracellular signaling pathways: a systematic review."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: TLR4, p38 MAPK and NFκB are involved in mediating pathogenic effects of aPL on different cell types and may be potential therapeutic targets in antiphospholipid syndrome.
    explanation: This identifies a specific innate signaling axis activated by aPL-beta2GPI complexes.
- name: Endothelial activation
  description: aPL signaling converts endothelial cells into a proadhesive, inflammatory, and procoagulant vascular surface.
  cell_types:
  - preferred_term: endothelial cell
    term:
      id: CL:0000115
      label: endothelial cell
  downstream:
  - target: Complement activation
    description: Activated endothelium amplifies local inflammatory and complement cascades.
    causal_link_type: DIRECT
    evidence:
    - reference: PMID:33878780
      reference_title: "Impaired Fibrinolysis in the Antiphospholipid Syndrome."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: aPL induce excessive activation of the endothelium, monocytes, and platelets in consort with aberrations in hemostasis/clotting, fibrinolytic system, and complement activation.
      explanation: This supports complement activation as part of the downstream inflammatory program coupled to endothelial activation.
  - target: Arterial and venous thrombosis
    description: Activated endothelium promotes coagulation and vascular occlusion.
    causal_link_type: DIRECT
    evidence:
    - reference: PMID:20822807
      reference_title: "Antiphospholipid syndrome."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: Antiphospholipid antibodies promote activation of endothelial cells, monocytes, and platelets; and overproduction of tissue factor and thromboxane A2.
      explanation: This supports endothelial activation as a direct contributor to overt thrombosis.
  evidence:
  - reference: PMID:20822807
    reference_title: "Antiphospholipid syndrome."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: Antiphospholipid antibodies promote activation of endothelial cells, monocytes, and platelets; and overproduction of tissue factor and thromboxane A2.
    explanation: This review supports endothelial activation as a central APS mechanism.
- name: Monocyte tissue factor induction
  description: Activated monocytes upregulate tissue factor and intensify thrombin generation.
  cell_types:
  - preferred_term: monocyte
    term:
      id: CL:0000576
      label: monocyte
  downstream:
  - target: Arterial and venous thrombosis
    description: Monocyte-derived tissue factor accelerates coagulation and promotes thrombus formation.
    causal_link_type: DIRECT
    evidence:
    - reference: PMID:20822807
      reference_title: "Antiphospholipid syndrome."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: Antiphospholipid antibodies promote activation of endothelial cells, monocytes, and platelets; and overproduction of tissue factor and thromboxane A2.
      explanation: This directly supports the edge from monocyte tissue factor induction to thrombosis.
  evidence:
  - reference: PMID:20822807
    reference_title: "Antiphospholipid syndrome."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: Antiphospholipid antibodies promote activation of endothelial cells, monocytes, and platelets; and overproduction of tissue factor and thromboxane A2.
    explanation: This review supports monocyte activation with tissue factor overproduction as a core APS mechanism.
- name: Platelet activation
  description: Platelets exposed to aPL signaling become activated and generate thromboxane-dependent prothrombotic amplification.
  cell_types:
  - preferred_term: platelet
    term:
      id: CL:0000233
      label: platelet
  biological_processes:
  - preferred_term: platelet activation
    term:
      id: GO:0030168
      label: platelet activation
  downstream:
  - target: Arterial and venous thrombosis
    description: Activated platelets reinforce thrombus growth and stabilize vascular occlusion.
    causal_link_type: DIRECT
    evidence:
    - reference: PMID:20822807
      reference_title: "Antiphospholipid syndrome."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: Antiphospholipid antibodies promote activation of endothelial cells, monocytes, and platelets; and overproduction of tissue factor and thromboxane A2.
      explanation: This supports platelet activation and thromboxane signaling as a direct contributor to APS thrombosis.
  evidence:
  - reference: PMID:20822807
    reference_title: "Antiphospholipid syndrome."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: Antiphospholipid antibodies promote activation of endothelial cells, monocytes, and platelets; and overproduction of tissue factor and thromboxane A2.
    explanation: This review supports platelet activation as a discrete prothrombotic mechanism in APS.
  - reference: PMID:33878780
    reference_title: "Impaired Fibrinolysis in the Antiphospholipid Syndrome."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: aPL induce excessive activation of the endothelium, monocytes, and platelets in consort with aberrations in hemostasis/clotting, fibrinolytic system, and complement activation.
    explanation: This confirms platelet activation as part of a broader APS prothrombotic program.
- name: Complement activation
  description: Complement cascade activation amplifies vascular inflammation, thrombosis, and placental injury in APS.
  biological_processes:
  - preferred_term: complement activation
    term:
      id: GO:0006956
      label: complement activation
  downstream:
  - target: Impaired fibrinolysis
    description: Complement-linked inflammatory hemostasis shifts clot remodeling toward persistence.
    causal_link_type: INDIRECT_KNOWN_INTERMEDIATES
    intermediate_mechanisms:
    - inflammatory hemostatic amplification
    - reduced fibrin clearance
    evidence:
    - reference: PMID:33878780
      reference_title: "Impaired Fibrinolysis in the Antiphospholipid Syndrome."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: aPL induce excessive activation of the endothelium, monocytes, and platelets in consort with aberrations in hemostasis/clotting, fibrinolytic system, and complement activation.
      explanation: This supports complement activation as part of a linked hemostatic disturbance that includes impaired fibrinolysis.
  - target: Placental immune injury
    description: Complement deposition at the maternal-fetal interface promotes placental inflammation and perfusion failure.
    causal_link_type: INDIRECT_KNOWN_INTERMEDIATES
    intermediate_mechanisms:
    - placental immune complex deposition
    - impaired placental perfusion
    evidence:
    - reference: PMID:19557318
      reference_title: "Predictors of pregnancy outcome in antiphospholipid syndrome: a review."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: Moreover low levels of complement components are related to an increased incidence of obstetrical complications, suggesting that placental deposition of immune complexes and activation of complement cascade may contribute to placental failure APS related.
      explanation: This supports the mechanistic branch from complement activation to placental injury.
  evidence:
  - reference: PMID:20822807
    reference_title: "Antiphospholipid syndrome."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: Complement activation might have a central pathogenetic role.
    explanation: This review identifies complement as a core amplifier of APS pathogenesis.
- name: Impaired fibrinolysis
  description: Reduced fibrin clearance allows APS-associated clots to persist, propagate, and recur.
  biological_processes:
  - preferred_term: blood coagulation
    term:
      id: GO:0007596
      label: blood coagulation
  - preferred_term: fibrinolysis
    term:
      id: GO:0042730
      label: fibrinolysis
  downstream:
  - target: Arterial and venous thrombosis
    description: Failure to lyse fibrin-rich clots contributes to recurrent thrombosis in arteries, veins, and microvessels.
    causal_link_type: DIRECT
    evidence:
    - reference: PMID:33878780
      reference_title: "Impaired Fibrinolysis in the Antiphospholipid Syndrome."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: Impaired fibrinolysis has been found in APS patients with thrombotic as well as obstetric manifestations.
      explanation: This supports the causal contribution of fibrinolytic failure to overt thrombotic APS manifestations.
  evidence:
  - reference: PMID:33878780
    reference_title: "Impaired Fibrinolysis in the Antiphospholipid Syndrome."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: Impaired fibrinolysis has been found in APS patients with thrombotic as well as obstetric manifestations.
    explanation: This establishes impaired fibrinolysis as a discrete APS mechanism rather than part of a bundled prothrombotic state.
- name: Arterial and venous thrombosis
  description: Recurrent venous, arterial, and small-vessel thrombosis is the central clinical consequence of APS procoagulant signaling.
  downstream:
  - target: Organ ischemia and damage accrual
    description: Vascular occlusion reduces tissue perfusion and causes cumulative neurologic, renal, pulmonary, and other organ injury.
    causal_link_type: DIRECT
    evidence:
    - reference: PMID:22247356
      reference_title: "Morbidity, mortality, and organ damage in patients with antiphospholipid syndrome."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: After a mean followup of 7.55 years, 29% of patients experienced organ damage and 5 died... Neurologic damage is the most common cause of morbidity.
      explanation: This supports the direct progression from recurrent thrombosis to cumulative organ damage in APS.
  - target: Catastrophic microvascular thrombosis
    description: Diffuse small-vessel occlusion can escalate into thrombotic microangiopathy with acute multiorgan failure.
    causal_link_type: INDIRECT_KNOWN_INTERMEDIATES
    intermediate_mechanisms:
    - disseminated thrombotic microangiopathy
    - acute multiorgan small-vessel occlusion
    evidence:
    - reference: PMID:26753212
      reference_title: "[Catastrophic antiphospholipid syndrome]."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: The syndrome develops over a short period of time with acute multi-organ failure, including kidney, respiratory, cardiovascular, central nervous system and adrenal glands, often associated with disseminated thrombotic microangiopathy.
      explanation: This supports catastrophic APS as a severe downstream extension of APS thrombosis through disseminated microvascular occlusion.
  evidence:
  - reference: PMID:20822807
    reference_title: "Antiphospholipid syndrome."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: The antiphospholipid syndrome causes venous, arterial, and small-vessel thrombosis; pregnancy loss; and preterm delivery for patients with severe pre-eclampsia or placental insufficiency.
    explanation: This review defines recurrent venous, arterial, and small-vessel thrombosis as a core APS event.
  - reference: PMID:24321419
    reference_title: "Risk factors for arterial thrombosis in antiphospholipid syndrome."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: Antiphospholipid syndrome (APS) is associated with the risk of both arterial and venous thrombosis.
    explanation: This provides independent support that APS drives both arterial and venous thrombotic events.
- name: Placental immune injury
  description: At the maternal-fetal interface, aPL-driven inflammation, trophoblast dysfunction, and impaired placental perfusion produce the obstetric branch of APS.
  cell_types:
  - preferred_term: trophoblast cell
    term:
      id: CL:0000351
      label: trophoblast cell
  locations:
  - preferred_term: placenta
    term:
      id: UBERON:0001987
      label: placenta
  downstream:
  - target: Pregnancy morbidity
    description: Placental dysfunction leads to miscarriage, preeclampsia, fetal growth restriction, and preterm delivery.
    causal_link_type: DIRECT
    evidence:
    - reference: PMID:19665761
      reference_title: "Mechanisms of antiphospholipid antibody-associated pregnancy complications."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: Women with antiphospholipid syndrome (APS) and antiphospholipid antibodies (aPL) are at high risk for recurrent spontaneous miscarriage and late pregnancy complications, such as preeclampsia and preterm labor.
      explanation: This supports the direct edge from placental immune injury to recurrent miscarriage and late obstetric complications.
  evidence:
  - reference: PMID:19665761
    reference_title: "Mechanisms of antiphospholipid antibody-associated pregnancy complications."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: Recent clinical and experimental observations suggest that the pathophysiology of pregnancy failure in patients with APS may involve inflammation at the maternal-fetal interface and disruption of normal trophoblast function and survival, rather than a pro-thrombotic event.
    explanation: This supports placental inflammation and trophoblast dysfunction as a distinct APS mechanism.
  - reference: PMID:19557318
    reference_title: "Predictors of pregnancy outcome in antiphospholipid syndrome: a review."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: It provides a non-invasive method for the study of uteroplacental blood flow, being able to detect a condition of impaired placental perfusion, due to the presence of circulating antiphospholipid antibodies (aPL).
    explanation: This supports impaired placental perfusion as part of the obstetric APS pathway.
- name: Pregnancy morbidity
  description: Placental insufficiency in APS leads to recurrent miscarriage, preeclampsia, fetal growth restriction, and preterm delivery.
  evidence:
  - reference: PMID:20822807
    reference_title: "Antiphospholipid syndrome."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: The antiphospholipid syndrome causes venous, arterial, and small-vessel thrombosis; pregnancy loss; and preterm delivery for patients with severe pre-eclampsia or placental insufficiency.
    explanation: This supports pregnancy loss and preterm delivery as key downstream obstetric outcomes of APS.
  - reference: PMID:19557318
    reference_title: "Predictors of pregnancy outcome in antiphospholipid syndrome: a review."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: In pregnant women, antiphospholipid syndrome (APS) is associated with an increased risk of preeclampsia, fetal intrauterine growth restriction, and other complications related to uteroplacental insufficiency.
    explanation: This supports the broader set of placental-insufficiency phenotypes that define obstetric APS.
- name: Organ ischemia and damage accrual
  description: Recurrent thrombotic occlusion causes cumulative injury across the brain, kidneys, lungs, and other organs.
  locations:
  - preferred_term: brain
    term:
      id: UBERON:0000955
      label: brain
  - preferred_term: kidneys
    term:
      id: UBERON:0002113
      label: kidney
  - preferred_term: lungs
    term:
      id: UBERON:0002048
      label: lung
  evidence:
  - reference: PMID:22247356
    reference_title: "Morbidity, mortality, and organ damage in patients with antiphospholipid syndrome."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: After a mean followup of 7.55 years, 29% of patients experienced organ damage and 5 died... Neurologic damage is the most common cause of morbidity.
    explanation: This cohort demonstrates cumulative damage accrual in APS over time.
  - reference: PMID:27198137
    reference_title: "Renal involvement in primary antiphospholipid syndrome."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: The kidney is a major target organ in both primary and secondary antiphospholipid syndrome... APSN is a vascular nephropathy characterized by small vessel vaso-occlusive lesions.
    explanation: This supports kidney injury as a representative organ-damage consequence of APS vaso-occlusion.
  - reference: PMID:36575066
    reference_title: "[Venous thromboembolism in antiphosholipid syndrome]."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: Venous thromboembolism belongs to the most frequent clinical manifestation of this syndrome... we summarised basic pathophysiological mechanisms of venous thrombosis and lung embolism development.
    explanation: This supports pulmonary injury through thromboembolic complications in APS.
  - reference: PMID:38368768
    reference_title: "Risk factors for damage accrual in primary antiphospholipid syndrome: A retrospective single-center cohort study."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: APS patients had a higher frequency of damage accrual. Microangiopathy and non-criteria manifestations were independent risk factors for damage accrual.
    explanation: This confirms that recurrent vascular injury in APS produces long-term damage accrual.
- name: Catastrophic microvascular thrombosis
  description: Catastrophic APS represents diffuse small-vessel thrombosis with thrombotic microangiopathy, hematologic injury, and acute multiorgan failure.
  locations:
  - preferred_term: brain
    term:
      id: UBERON:0000955
      label: brain
  - preferred_term: kidneys
    term:
      id: UBERON:0002113
      label: kidney
  - preferred_term: lungs
    term:
      id: UBERON:0002048
      label: lung
  evidence:
  - reference: PMID:26753212
    reference_title: "[Catastrophic antiphospholipid syndrome]."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: Catastrophic antiphospholipid syndrome is the most dangerous form of the antiphospholipid syndrome, which is characterized by rapid onset of thrombosis in small vessels of many organs and intravascular coagulation, thrombocytopenia and hemolytic anemia.
    explanation: This defines CAPS as widespread small-vessel thrombosis with hematologic complications.
  - reference: PMID:26753212
    reference_title: "[Catastrophic antiphospholipid syndrome]."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: The syndrome develops over a short period of time with acute multi-organ failure, including kidney, respiratory, cardiovascular, central nervous system and adrenal glands, often associated with disseminated thrombotic microangiopathy.
    explanation: This supports acute multiorgan failure from disseminated microvascular thrombosis as the most severe APS mechanistic outcome.
phenotypes:
- category: Thrombosis
  name: Deep Vein Thrombosis
  frequency: FREQUENT
  diagnostic: true
  evidence:
  - reference: PMID:36575066
    reference_title: "[Venous thromboembolism in antiphosholipid syndrome]."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: Venous thromboembolism belongs to the most frequent clinical manifestation of this syndrome.
    explanation: The reference mentions that venous thromboembolism, which includes deep vein thrombosis, is a frequent manifestation in Antiphospholipid Syndrome (APS).
  - reference: PMID:10961585
    reference_title: "Catastrophic antiphospholipid syndrome."
    supports: PARTIAL
    evidence_source: HUMAN_CLINICAL
    snippet: In its classic presentation, the antiphospholipid syndrome manifests a combination of venous or arterial thrombosis... The manifestations often include a moderate thrombocytopenia and, less commonly, hemolysis.
    explanation: While it confirms the presence of venous thrombosis, including potential complications like stroke, it does not definitively confirm deep vein thrombosis and pulmonary embolism as common sequelae in all cases.
  - reference: PMID:12627666
    reference_title: "Antiphospholipid thrombosis syndromes."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: The relative frequency of ACLAs in association with arterial and venous thrombosis strongly suggests that they should be looked for in any individual with unexplained thrombosis; all three idiotypes (IgG, IgA, and IgM) should be assessed.
    explanation: Venous thrombosis, including deep vein thrombosis and pulmonary embolism, is frequently observed in APS.
  phenotype_term:
    preferred_term: Deep Vein Thrombosis
    term:
      id: HP:0004850
      label: Recurrent deep vein thrombosis
- category: Pregnancy-Related
  name: Preterm Birth
  context: Pregnancy
  evidence:
  - reference: PMID:26815583
    reference_title: "[Antiphospholipid syndrome and pregnancy]."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: Obstetric morbidity includes recurrent first trimester loss, stillbirth, intrauterine death, preeclam-psia, premature birth and fetal growth restriction
    explanation: The reference lists premature birth (preterm birth) as a form of obstetric morbidity associated with APS, supporting its categorization as a pregnancy-related phenotype.
  - reference: PMID:36756665
    reference_title: "Clinical phenotype, treatment strategy and pregnancy outcome of non-criteria obstetric antiphospholipid syndrome."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: The pregnancy outcomes were not significantly different between NC-OAPS and OAPS groups.
    explanation: The evidence suggests that patients with APS (OAPS) can experience similar pregnancy outcomes to those without the specific criteria of classical APS, which includes preterm birth.
  - reference: PMID:34280554
    reference_title: "Pregnancy outcome predictors in antiphospholipid syndrome: A systematic review and meta-analysis."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: Patients with lupus anticoagulant positivity had an increased risk of preeclampsia (OR 2.10, p = 0.02, I2 = 48%), SGA (OR 1.78, p < 0.01, I2 = 0%) and preterm birth (OR 3.56, p = 0.01, I2 = 48%)
    explanation: The meta-analysis found that APS patients, especially those with lupus anticoagulant positivity, have an increased risk of preterm birth, supporting the statement that APS phenotypes include pregnancy-related complications such as preterm birth.
  phenotype_term:
    preferred_term: Preterm Birth
    term:
      id: HP:0001622
      label: Premature birth
- category: Hematologic
  name: Thrombocytopenia
  evidence:
  - reference: PMID:8952756
    reference_title: "Thrombocytopenia in the antiphospholipid syndrome: pathophysiology, clinical relevance and treatment."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: a variable degree of thrombocytopenia occurs in approximately 20-40% of the patients with APS
    explanation: Thrombocytopenia is a hematologic phenotype observed in APS patients.
  - reference: PMID:21303834
    reference_title: "Task Force on Catastrophic Antiphospholipid Syndrome (APS) and Non-criteria APS Manifestations (II): thrombocytopenia and skin manifestations."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: This article summarizes the studies analyzed on thrombocytopenia and skin manifestations
    explanation: Thrombocytopenia is mentioned as a manifestation studied in APS.
  - reference: PMID:29316193
    reference_title: "Thrombocytopenia in high-risk patients with antiphospholipid syndrome."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: Thrombocytopenia is the most common non-criteria hematological feature in patients with antiphospholipid syndrome (APS).
    explanation: Thrombocytopenia is a significant hematologic feature observed in APS.
  phenotype_term:
    preferred_term: Thrombocytopenia
    term:
      id: HP:0001873
      label: Thrombocytopenia
- category: Cardiovascular
  frequency: FREQUENT
  name: Cardiac Valve Disease
  evidence:
  - reference: PMID:17916990
    reference_title: "The Heart and APS."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: Valvular involvement is the most common manifestation with a prevalence of 82% detected by transesophageal echocardiography. Symmetrical, nodular thickening of the mitral and/or aortic valves is characteristic.
    explanation: This reference indicates that cardiac valve disease, specifically valvular involvement, is a common manifestation in patients with antiphospholipid syndrome (APS).
  - reference: PMID:10852159
    reference_title: "Cardiac valve diseases and antiphospholipid syndrome."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: Cardiac valve diseases and antiphospholipid syndrome.
    explanation: The title of this reference directly connects cardiac valve diseases with APS, supporting the statement.
  - reference: PMID:1733383
    reference_title: "Valvular heart disease in the primary antiphospholipid syndrome."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: Valvular involvement is frequently found in patients with the primary antiphospholipid syndrome.
    explanation: This study shows a significant prevalence of cardiac valvular involvement in patients with primary APS.
  - reference: PMID:30614053
    reference_title: "Valvular heart disease in Antiphospholipid antibody syndrome: Isolated Tricuspid stenosis."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: Most commonly mitral valve is affected followed by aortic and then tricuspid valve.
    explanation: This report confirms that cardiac valve disease is a manifestation of APS, most commonly affecting the mitral valve.
  - reference: PMID:1442504
    reference_title: "Cardiac manifestations of the antiphospholipid syndrome."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: The earliest reports were of valvular disease, including verrucous endocarditis, as well as valvular thickening and insufficiency.
    explanation: This review discusses various cardiac abnormalities associated with APS, including valvular disease.
  - reference: PMID:23456852
    reference_title: "Valvular heart disease in antiphospholipid syndrome."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: Heart valve disease (HVD) is the most frequent cardiac manifestation in patients with antiphospholipid syndrome (APS), with prevalence of 30 %.
    explanation: This review supports classifying cardiac valve disease as a frequent APS phenotype rather than an occasional one.
  - reference: PMID:12402416
    reference_title: "Cardiac valvulopathy in the antiphospholipid syndrome."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: The valvulopathy in APS is quite common and may lead to valve replacement.
    explanation: This review explicitly describes APS valvulopathy as common, supporting a frequent phenotype assignment.
- category: Pregnancy-Related
  context: Pregnancy
  frequency: OCCASIONAL
  name: Preeclampsia
  evidence:
  - reference: PMID:26815583
    reference_title: "[Antiphospholipid syndrome and pregnancy]."
    supports: PARTIAL
    evidence_source: HUMAN_CLINICAL
    snippet: Obstetric morbidity includes recurrent first trimester loss, stillbirth, intrauterine death, preeclam-psia, premature birth and fetal growth restriction
    explanation: The literature supports the association of antiphospholipid syndrome with preeclampsia, but it does not specify that the frequency is 'occasional'.
  - reference: PMID:32413497
    reference_title: "Antiphospholipid syndrome."
    supports: PARTIAL
    evidence_source: HUMAN_CLINICAL
    snippet: Its major presentations are thrombotic (arterial, venous, or microvascular) and pregnancy morbidity (miscarriages, late intrauterine fetal demise, and severe pre-eclampsia).
    explanation: The literature supports the association of antiphospholipid syndrome with preeclampsia, but it does not specify that the frequency is 'occasional'.
  phenotype_term:
    preferred_term: Preeclampsia
    term:
      id: MONDO:0005081
      label: preeclampsia
- category: Hematologic
  frequency: FREQUENT
  name: Thrombocytopenia
  evidence:
  - reference: PMID:35536236
    reference_title: "Thrombocytopenia in primary antiphospholipid syndrome: association with prognosis and clinical implications."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: Thrombocytopenia, a frequent clinical manifestation in patients with APS, could be an independent predictor of recurrent thrombotic, obstetric and severe extracriteria events.
    explanation: The study indicates thrombocytopenia is a frequent clinical manifestation in patients with primary APS.
  - reference: PMID:17426356
    reference_title: "Hughes Syndrome: the antiphospholipid syndrome--a clinical overview."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: Other features include recurrent miscarriage, thrombocytopenia, and livedo reticularis.
    explanation: Thrombocytopenia is mentioned as a clinical feature of APS, supporting its frequent occurrence.
  - reference: PMID:18417261
    reference_title: "The hematologic manifestations of the antiphospholipid syndrome."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: Thrombocytopenia is frequently found in APS patients, its incidence has ranged from 22-42% in different series.
    explanation: The incidence range of 22-42% indicates that thrombocytopenia is a frequent hematologic manifestation in APS patients.
  phenotype_term:
    preferred_term: Thrombocytopenia
    term:
      id: HP:0001873
      label: Thrombocytopenia
- category: Dermatologic
  frequency: OCCASIONAL
  name: Livedo Reticularis
  evidence:
  - reference: PMID:26223086
    reference_title: "Livedo Reticularis: An Enigma."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: Livedo reticularis is a common cutaneous manifestation of APS and may be a prognostic marker of more severe disease.
    explanation: This reference states that livedo reticularis is a common cutaneous manifestation of APS, supporting its categorization as a dermatologic manifestation.
  - reference: PMID:9204065
    reference_title: "Antiphospholipid syndrome and the skin."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: Cutaneous manifestations may occur as the first sign of antiphospholipid syndrome. These include livedo reticularis...
    explanation: This reference confirms that livedo reticularis is one of the cutaneous manifestations of APS.
  - reference: PMID:35697016
    reference_title: "Analysis of Serbian Primary Antiphospholipid Syndrome Patients Confirmed a Strong Association Between Livedo Reticularis and Arterial Thrombosis: A National Cross-Sectional Cohort Study."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: This cross-sectional analysis of a large cohort of Serbian PAPS patients confirmed a strong relationship between livedo reticularis and arterial thrombosis...
    explanation: This reference supports the association of livedo reticularis with APS, indicating its presence in patients with the syndrome.
  - reference: PMID:36112747
    reference_title: "Risk of livedo with antiphospholipid antibodies in patients with systemic lupus erythematosus: A systematic review and meta-analysis."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: Livedo is a well-known skin condition in patients with systemic lupus erythematosus (SLE) which correspond to small vessels involvement.
    explanation: This reference discusses the prevalence of livedo in patients with SLE and APS, supporting its categorization as a dermatologic manifestation.
  phenotype_term:
    preferred_term: Livedo Reticularis
    term:
      id: HP:0033505
      label: Livedo reticularis
- category: Neurologic
  frequency: OCCASIONAL
  name: Migraine Headaches
  evidence:
  - reference: PMID:27423434
    reference_title: "Antiphospholipid syndrome (APS) revisited: Would migraine headaches be included in future classification criteria?"
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: Migraine is the most commonly reported type of headache in APS/aPL-positive patients.
    explanation: The literature indicates that migraine headaches are frequently reported in patients with Antiphospholipid Syndrome (APS), supporting the statement that they are an occasional neurological manifestation.
  - reference: PMID:29756580
    reference_title: "Subtypes of Antiphospholipid Antibodies in Neurologic Disorders: An Observational Study."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: Cerebral vascular accident (33%), retinal artery/vein occlusion (21%), and seizure (20%) were the most frequent presentations among the patients.
    explanation: This study supports the association between APS and neurological manifestations, including migraines, although it does not provide specific frequency data for migraines.
  - reference: PMID:27658514
    reference_title: "'Non-Criteria' Neurologic Manifestations of Antiphospholipid Syndrome: A Hidden Kingdom to be Discovered."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: Although in the most recently updated (2006) APS classification criteria, the neurological manifestations encompass only transient ischemic attack and stroke, diverse 'non-criteria' neurological disorders or manifestations (i.e., headache, migraine...) have been observed in APS patients.
    explanation: This reference supports the occurrence of migraines as a neurological manifestation in APS patients, even though it is not part of the official classification criteria.
- category: Cardiovascular
  name: Pulmonary Embolism
  frequency: FREQUENT
  notes: Clot migration from deep veins to pulmonary arteries
  evidence:
  - reference: PMID:17165009
    reference_title: "[Antiphospholipid syndrome]."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: A common cause of the huge variety of clinical manifestations is vaso-occlusive disease and not vasculitis in venous or arterial blood vessels of different sizes and sites (i.e. deep vein thrombosis, pulmonary embolism, cerebrovascular disease).
    explanation: This review explicitly lists pulmonary embolism among the vaso-occlusive manifestations of APS.
  - reference: PMID:23073594
    reference_title: "[Analysis of risk factors in development of thrombosis in patients with antiphospholipid syndrome]."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: Deep vein thrombosis of lower extremity (37.7%) and cerebral infarction (24.59%) were the most common thrombosis events, and then pulmonary embolism, thrombotic microangiopathy and renal artery thrombosis were also common in APS patients.
    explanation: This cohort study identifies pulmonary embolism as a common thrombotic manifestation in APS patients.
  phenotype_term:
    preferred_term: Pulmonary embolism
    term:
      id: HP:0002204
      label: Pulmonary embolism
- category: Neurologic
  name: Stroke
  frequency: FREQUENT
  notes: Arterial thrombosis causing cerebrovascular accident
  evidence:
  - reference: PMID:24741580
    reference_title: "Revisiting the molecular mechanism of neurological manifestations in antiphospholipid syndrome: beyond vascular damage."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: Typically, neurological manifestations of APS include thrombosis of cerebral vessels leading to stroke and requiring prompt initiation of treatment with antiplatelet drugs or anticoagulant therapy.
    explanation: This review directly supports stroke as a common neurologic thrombotic manifestation of APS.
  - reference: PMID:23073594
    reference_title: "[Analysis of risk factors in development of thrombosis in patients with antiphospholipid syndrome]."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: Deep vein thrombosis of lower extremity (37.7%) and cerebral infarction (24.59%) were the most common thrombosis events, and then pulmonary embolism, thrombotic microangiopathy and renal artery thrombosis were also common in APS patients.
    explanation: This cohort study identifies cerebral infarction as one of the most common thrombotic events in APS.
  phenotype_term:
    preferred_term: Stroke
    term:
      id: HP:0001297
      label: Stroke
biochemical:
- name: Antiphospholipid Antibodies
  presence: Positive
  evidence:
  - reference: PMID:26307097
    reference_title: "Diagnosis and therapy of antiphospholipid syndrome."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: According to current guidelines, 3 tests (lupus anticoagulant, anticardiolipin, and anti beta2-glycoprotein I antibodies) are officially recommended to assess the presence of antiphospholipid antibodies.
    explanation: The presence of these specific antibodies is used to diagnose antiphospholipid syndrome, directly supporting the statement.
- name: Lupus Anticoagulant
  presence: Positive
  evidence:
  - reference: PMID:8712801
    reference_title: "The lupus anticoagulant/antiphospholipid syndrome."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: Recent data suggest strongly that lupus anticoagulants (LACs) and anticardiolipin antibodies (ACAs) are antibodies to protein-phospholipid complexes.
    explanation: The literature identifies lupus anticoagulant as part of the antiphospholipid syndrome, supporting its presence in this condition.
  - reference: PMID:36032074
    reference_title: "Antiphospholipid antibodies are persistently positive at high titers. Additive value of platelet-bound C4d."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: As both platelet-bound C4d (PC4d) and aPL are associated with thrombosis in systemic lupus erythematosus (SLE)...
    explanation: High titers of antiphospholipid antibodies, including lupus anticoagulant, were confirmed to be persistently positive.
  - reference: PMID:20848817
    reference_title: "Antiphospholipid antibody syndrome."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: The 2006 International Consensus Statement on an Update of the Classification Criteria for Definite Antiphospholipid Syndrome has increased the time between the two laboratory studies required for diagnosis from 6 to 12 weeks. Antibody to beta2 glycoprotein 1 has been included as a criterion.
    explanation: Lupus anticoagulant presence is included in the diagnostic criteria for antiphospholipid syndrome.
  - reference: PMID:23219767
    reference_title: "Correct laboratory approach to APS diagnosis and monitoring."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: Triple positivity (positive Lupus Anticoagulant, anticardiolipin and anti beta2-glycoptrotein I antibodies) identifies the pathogenic autoantibody.
    explanation: Lupus anticoagulant is considered a significant marker for diagnosing antiphospholipid syndrome.
- name: Anti-Cardiolipin Antibodies
  presence: Positive
  evidence:
  - reference: PMID:15804703
    reference_title: "Anticardiolipin and anti-beta-2-glycoprotein I antibodies."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: The anticardiolipin (aCL) antibody test was first established in 1983, using cardiolipin (negatively charged phospholipid) as an antigen in a solid-phase immunoassay. It was first applied to the study of systemic lupus erythematosus patients, and was found associated with thromboses and recurrent pregnancy losses. The wide use of this test was determinant in the definition of the 'aCL or antiphospholipid syndrome' (APS).
    explanation: The presence of anticardiolipin antibodies is associated with antiphospholipid syndrome (APS).
  - reference: PMID:35728601
    reference_title: "Antiphospholipid Syndrome in Patients with Venous Thromboembolism."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: The evaluation of aPL is standardized using immunological tests for anticardiolipin and anti-beta2-glycoprotein I.
    explanation: Anticardiolipin antibodies are used in the evaluation and diagnosis of antiphospholipid syndrome.
  - reference: PMID:10977230
    reference_title: "The antiphospholipid antibody syndrome."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: Antiphospholipid syndrome includes elevation of either the lupus anticoagulant titer or the anticardiolipin antibody titer on two occasions, separated by 6 weeks in a patient with an episode of thrombosis.
    explanation: Elevated anticardiolipin antibody titer is a criterion for diagnosing antiphospholipid syndrome.
- name: Beta-2 Glycoprotein I Antibodies
  presence: Positive
  evidence:
  - reference: PMID:7795615
    reference_title: "Anti-beta 2-glycoprotein I antibodies: a marker of antiphospholipid syndrome?"
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: Anticardiolipin (aCL) and anti-beta 2-glycoprotein I(anti beta 2GPI) antibodies have been shown in animal models as not cross-reacting antibody populations.
    explanation: The abstract mentions the detection and study of anti-beta 2GPI antibodies, indicating their presence.
  - reference: PMID:25292011
    reference_title: "Thrombotic Primary Antiphospholipid Syndrome: the profile of antibody positivity in patients from North India."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: abeta2 Gp1 (anti-betaeta-2 glycoprotein 1) antibody and LAC (lupus anticoagulant) of 1222 consecutive patients referred to the coagulation laboratory work-up for a hypercoagulable/thrombophilic state.
    explanation: The study evaluates the frequency of APS including the presence of anti-beta 2 glycoprotein 1 antibodies, supporting their association with the syndrome.
  - reference: PMID:21046294
    reference_title: "Autoantibodies directed against domain I of beta2-glycoprotein I."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: Although many antigens have been identified in relation to the antiphospholipid syndrome, beta2-glycoprotein I is regarded as clinically most significant.
    explanation: The connection between beta2-glycoprotein I antibodies and APS is clearly established in the context of the syndrome.
  - reference: PMID:28347805
    reference_title: "β2-glycoprotein I and its antibodies involve in the pathogenesis of the antiphospholipid syndrome."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: β2-glycoprotein I is a phospholipid-binding glycoprotein, and its antibodies have been reported to correlate strongly with thrombotic risk and play putative role in the pathogenesis of APS, whereas the biofunctions of anti-β2-glycoprotein I antibodies remain largely uncertain
    explanation: The involvement of beta2-glycoprotein I antibodies in APS and their role in pathogenesis is discussed in detail.
- name: Anti-Smith Antibodies
  presence: Negative
  evidence:
  - reference: PMID:24420722
    reference_title: "Distinct antibody profile: a clue to primary antiphospholipid syndrome evolving into systemic lupus erythematosus?"
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: anti-Smith (Sm) antibodies were not detected in both groups.
    explanation: The study indicates that anti-Smith antibodies were not detected in the APS/SLE group, confirming that anti-Smith antibodies are negative in patients with APS.
genetic:
- name: HLA-DR7
  presence: Positive
  evidence:
  - reference: PMID:8792513
    reference_title: "The immunogenetics of the antiphospholipid syndrome, anticardiolipin antibodies, and lupus anticoagulant."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: This familial tendency could be genetically determined, because APS, aCL, and LAC occur in families carrying haplotypes which contain HLA-DR4, -DR7, and -DRw53.
    explanation: This review directly supports HLA-DR7 as a reported susceptibility-associated haplotype in APS families.
  - reference: PMID:8792513
    reference_title: "The immunogenetics of the antiphospholipid syndrome, anticardiolipin antibodies, and lupus anticoagulant."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: Population studies on primary APS also indicate that HLA genes have a role in conferring susceptibility to develop primary APS. Again, DR4, DR7, and DRw53 are the relevant loci.
    explanation: This further supports HLA-DR7 as one of the repeatedly implicated HLA loci in primary APS susceptibility.
- name: HLA-DR4
  presence: Positive
  evidence:
  - reference: PMID:8792513
    reference_title: "The immunogenetics of the antiphospholipid syndrome, anticardiolipin antibodies, and lupus anticoagulant."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: This familial tendency could be genetically determined, because APS, aCL, and LAC occur in families carrying haplotypes which contain HLA-DR4, -DR7, and -DRw53.
    explanation: This supports HLA-DR4 as part of APS-associated family haplotypes.
  - reference: PMID:8792513
    reference_title: "The immunogenetics of the antiphospholipid syndrome, anticardiolipin antibodies, and lupus anticoagulant."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: Population studies on primary APS also indicate that HLA genes have a role in conferring susceptibility to develop primary APS. Again, DR4, DR7, and DRw53 are the relevant loci.
    explanation: This provides additional support that DR4 is among the HLA loci repeatedly implicated in primary APS susceptibility.
environmental:
- name: Smoking
  presence: Positive
  evidence:
  - reference: PMID:15658543
    reference_title: "[Antiphospholipid syndrome and exogenic risk factors in thromboses]."
    supports: PARTIAL
    evidence_source: HUMAN_CLINICAL
    snippet: The proportion of smokers was higher in APS patients, though smoking did not provoke thrombotic complications.
    explanation: Smoking was more common in APS cohorts, supporting it as a relevant exposure, although this study did not show smoking independently provoked thrombosis.
  exposure_term:
    preferred_term: Tobacco smoking exposure
    term:
      id: ECTO:6000029
      label: exposure to tobacco smoking
- name: Infection
  presence: Positive
  evidence:
  - reference: PMID:17531174
    reference_title: "Antiphospholipid antibodies in response to infection."
    supports: PARTIAL
    evidence_source: HUMAN_CLINICAL
    snippet: An association between infections and antiphospholipid antibodies (aPL) has been reported in several epidemiologic and experimental studies. Infection-induced aPL have been traditionally regarded as transient and were generally not associated with clinical features of antiphospholipid syndrome.
    explanation: The statement is partially supported because while there is an association between infections and antiphospholipid antibodies, infection-induced aPL are traditionally regarded as transient and not generally associated with the clinical features of antiphospholipid syndrome.
  - reference: PMID:22617823
    reference_title: "Infections and vaccines in the etiology of antiphospholipid syndrome."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "PURPOSE OF REVIEW: To present scientific evidence supporting the infectious origin for the antiphospholipid syndrome (APS) by molecular mimicry between pathogens, infection and vaccination with β2-glycoprotein I (β2-GPI) molecule."
    explanation: This review supports infection exposure as a plausible upstream trigger for APS-related autoimmunity through molecular mimicry.
  exposure_term:
    preferred_term: Infectious agent exposure
    term:
      id: ECTO:3000000
      label: exposure to organism
treatments:
- name: Long-term warfarin anticoagulation
  description: Vitamin K antagonist therapy for secondary prevention of recurrent venous or arterial thrombosis in thrombotic APS.
  treatment_term:
    preferred_term: pharmacotherapy
    term:
      id: MAXO:0000058
      label: pharmacotherapy
    therapeutic_agent:
    - preferred_term: warfarin
      term:
        id: CHEBI:10033
        label: warfarin
  evidence:
  - reference: PMID:18303659
    reference_title: "[Treatment of antiphospholipid syndrome]."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: Oral anticoagulants are the best available and most effective treatment for the secondary prevention of recurrent venous or arterial thrombosis. Patients with APS are treated with long-term therapy to prolong the INR to 2.0-3.0.
    explanation: This review supports long-term warfarin-based oral anticoagulation as standard secondary prevention for thrombotic APS.
  - reference: PMID:20822807
    reference_title: "Antiphospholipid syndrome."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: Therapy of thrombosis is based on long-term oral anticoagulation and patients with arterial events should be treated aggressively.
    explanation: This review confirms long-term oral anticoagulation as the basis of treatment for thrombotic APS.
- name: Heparin plus low-dose aspirin in pregnancy
  description: Combined anticoagulation and antiplatelet therapy used to reduce pregnancy loss and obstetric complications in obstetric APS.
  treatment_term:
    preferred_term: pharmacotherapy
    term:
      id: MAXO:0000058
      label: pharmacotherapy
    therapeutic_agent:
    - preferred_term: heparin
      term:
        id: CHEBI:28304
        label: heparin
    - preferred_term: aspirin
      term:
        id: CHEBI:15365
        label: acetylsalicylic acid
  evidence:
  - reference: PMID:18303659
    reference_title: "[Treatment of antiphospholipid syndrome]."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: Low-molecular-weight heparin in combination with low-aspirin dose is a reasonable strategy to avoid pregnancy loss in women with this syndrome.
    explanation: This supports combined heparin and aspirin therapy as standard management for obstetric APS.
  - reference: PMID:22341691
    reference_title: "[Pregnancy and antiphospholipid syndrome]."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: Heparin and low-dose aspirin are the main treatments.
    explanation: This pregnancy-focused review identifies heparin plus low-dose aspirin as the main treatment approach for obstetric APS.
- name: Adjunct hydroxychloroquine
  description: Adjunctive immunomodulatory therapy that may improve control of APS, especially in patients with systemic lupus erythematosus overlap or recurrent disease.
  treatment_term:
    preferred_term: pharmacotherapy
    term:
      id: MAXO:0000058
      label: pharmacotherapy
    therapeutic_agent:
    - preferred_term: hydroxychloroquine
      term:
        id: CHEBI:5801
        label: hydroxychloroquine
  evidence:
  - reference: PMID:20822807
    reference_title: "Antiphospholipid syndrome."
    supports: PARTIAL
    evidence_source: HUMAN_CLINICAL
    snippet: Hydroxychloroquine is a potential additional treatment for this syndrome.
    explanation: This review supports hydroxychloroquine as an adjunct rather than a standalone standard therapy in APS.
  - reference: PMID:26125104
    reference_title: "Update on the pathogenesis and treatment of the antiphospholipid syndrome."
    supports: PARTIAL
    evidence_source: HUMAN_CLINICAL
    snippet: The addition to standard treatment of pleiotropic agents such as hydroxychloroquine, statins and vitamin D could allow better disease control.
    explanation: This review supports hydroxychloroquine as an add-on strategy that may improve disease control in APS.
differential_diagnoses:
- name: Thrombotic thrombocytopenic purpura
  description: >-
    Thrombotic thrombocytopenic purpura can closely mimic catastrophic APS
    through thrombocytopenia, microangiopathic hemolysis, neurologic injury,
    renal dysfunction, and multiorgan ischemia.
  distinguishing_features:
  - Undetectable ADAMTS13 activity strongly favors thrombotic thrombocytopenic purpura.
  - Persistent antiphospholipid antibodies and the need for anticoagulation favor catastrophic APS over TTP.
  disease_term:
    preferred_term: thrombotic thrombocytopenic purpura
    term:
      id: MONDO:0018896
      label: thrombotic thrombocytopenic purpura
  evidence:
  - reference: PMID:10483019
    reference_title: "Relapsing catastrophic antiphospholipid antibody syndrome: a mimic for thrombotic thrombocytopenic purpura?"
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: The differential diagnosis of CAPS includes thrombotic thrombocytopenic purpura (TTP) and this distinction may be difficult, but essential, for appropriate therapy.
    explanation: This directly identifies TTP as a core differential diagnosis for catastrophic APS.
  - reference: PMID:25879992
    reference_title: "Differentiation between severe HELLP syndrome and thrombotic microangiopathy, thrombotic thrombocytopenic purpura and other imitators."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: The definitive marker for thrombotic thrombocytopenic purpura is undetectable ADAMTS 13 activity.
    explanation: This supports ADAMTS13 deficiency as a key laboratory feature distinguishing TTP from APS-related thrombotic microangiopathy.
- name: HELLP syndrome
  description: >-
    HELLP syndrome overlaps with obstetric APS and catastrophic APS through
    thrombocytopenia, hemolysis, liver injury, and severe pregnancy-associated
    maternal morbidity.
  distinguishing_features:
  - A pregnancy-specific pre-eclampsia context with hemolysis, elevated liver enzymes, and low platelet count favors HELLP syndrome.
  - Neurologic involvement, dialysis requirement, or absent disseminated intravascular coagulation raise concern for thrombotic microangiopathy or APS mimics rather than isolated HELLP.
  disease_term:
    preferred_term: HELLP syndrome
    term:
      id: MONDO:0008585
      label: HELLP syndrome
  evidence:
  - reference: PMID:25879992
    reference_title: "Differentiation between severe HELLP syndrome and thrombotic microangiopathy, thrombotic thrombocytopenic purpura and other imitators."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: Pre-eclampsia complicated by severe HELLP (hemolysis, elevated liver enzymes and low platelet count) syndrome is a multi-organ disease, and can be difficult to differentiate from thrombotic microangiopathy (appearing as thrombotic thrombocytopenic purpura or hemolytic uremic syndrome), acute fatty liver, systemic erythematous lupus, antiphospholipid syndrome and severe sepsis.
    explanation: This review explicitly names antiphospholipid syndrome among the major disorders that can be confused with severe HELLP syndrome.
  - reference: PMID:25879992
    reference_title: "Differentiation between severe HELLP syndrome and thrombotic microangiopathy, thrombotic thrombocytopenic purpura and other imitators."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: Relevant identifiers to establish the most accurate diagnosis include the frequency of each disease and anamnestic data. Frank hemolysis, need for dialysis, neurological involvement and absence of disseminated intravascular coagulation are indicative of thrombotic microangiopathy.
    explanation: This supports specific distinguishing features that help separate HELLP syndrome from APS-related thrombotic microangiopathy.
- name: Systemic lupus erythematosus
  description: >-
    Systemic lupus erythematosus frequently co-occurs with APS and may be
    mistaken for primary APS when antiphospholipid antibodies are present
    alongside broader systemic autoimmune findings.
  distinguishing_features:
  - SLE-specific nephropathy, arthritis, cutaneous or neurologic lupus manifestations, anti-dsDNA, anti-Sm, or high-titer ANA favor systemic lupus erythematosus.
  - Strictly defined primary APS can satisfy some lupus classification items without progressing to clinical SLE on long-term follow-up.
  disease_term:
    preferred_term: systemic lupus erythematosus
    term:
      id: MONDO:0007915
      label: systemic lupus erythematosus
  evidence:
  - reference: PMID:30005859
    reference_title: "Classification of primary antiphospholipid syndrome as systemic lupus erythematosus: Analysis of a cohort of 214 patients."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: We successively excluded patients with (1) at least one "SLE-specific" manifestation (biopsy-proven SLE nephropathy, arthritis, cutaneous, or neurologic SLE manifestations, pericarditis, autoimmune haemolytic anaemia, oral and nasal ulcers, non-scarring alopecia, anti-dsDNA, and anti-Sm antibodies), (2) any other autoimmune connective tissue disease, and/or (3) antinuclear antibodies >1/320.
    explanation: This cohort analysis outlines the clinical and serologic features used to distinguish SLE from primary APS.
  - reference: PMID:30005859
    reference_title: "Classification of primary antiphospholipid syndrome as systemic lupus erythematosus: Analysis of a cohort of 214 patients."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: Because 28% of our patients with longstanding and strictly defined PAPS could be mistakenly classified as SLE, they were at risk of deleterious therapeutic management.
    explanation: This directly supports SLE as an important diagnostic pitfall and differential diagnosis for primary APS.
clinical_trials:
- name: NCT05199909
  phase: PHASE_II
  status: RECRUITING
  description: >-
    Single-arm phase II study evaluating zanubrutinib for antiphospholipid
    syndrome with secondary thrombocytopenia.
  target_phenotypes:
  - preferred_term: Thrombocytopenia
    term:
      id: HP:0001873
      label: Thrombocytopenia
  evidence:
  - reference: clinicaltrials:NCT05199909
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: To evaluate the safety and efficacy of zanubrutinib in the treatment of antiphospholipid syndrome with secondary thrombocytopenia in 10 patients.
    explanation: This supports the study objective, intervention, and thrombocytopenia-focused APS population.
- name: NCT05671757
  phase: PHASE_I
  status: RECRUITING
  description: >-
    Dose-escalation safety trial of daratumumab in primary APS, designed to
    define tolerated dosing and early safety.
  evidence:
  - reference: clinicaltrials:NCT05671757
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: The purpose of this study is to see if the study medication, daratumumab, is safe to treat individuals with Anti-Phospholipid Syndrome (APS).
    explanation: This supports daratumumab as an actively recruiting investigational therapy for primary APS.
  - reference: clinicaltrials:NCT05671757
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: The primary objective is to determine the safety of daratumumab in APS defined as Dose Limiting Toxicities (DLTs) occurring during the dose escalation phase.
    explanation: This supports representing the combined Phase 1/2 study as a phase I-style dose-escalation safety trial in schema-constrained form.
  notes: >-
    ClinicalTrials.gov currently lists combined PHASE1 and PHASE2 designations;
    the schema entry uses PHASE_I because the primary endpoint is dose-limiting
    toxicity during escalation.
- name: NCT02157272
  phase: PHASE_III
  status: TERMINATED
  description: >-
    Randomized trial comparing rivaroxaban versus warfarin in high-risk
    triple-positive thrombotic APS.
  target_phenotypes:
  - preferred_term: Deep Vein Thrombosis
    term:
      id: HP:0004850
      label: Recurrent deep vein thrombosis
  - preferred_term: Stroke
    term:
      id: HP:0001297
      label: Stroke
  evidence:
  - reference: clinicaltrials:NCT02157272
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: Primary Study Objective(s) The primary objective is to demonstrate the non-inferiority of Rivaroxaban 20 mg (or 15mgqd in case of moderate renal insufficiency) versus warfarin (INR 2.0-3.0) with respect to the occurrence of the cumulative end point of incident acute thrombosis (arterial or venous) confirmed by appropriate imaging studies, major bleedings, and death in triple aPL-positive APS patients.
    explanation: This supports the anticoagulation comparison, high-risk APS population, and thrombotic endpoints addressed by the trial.
- name: NCT04275778
  phase: PHASE_II
  status: UNKNOWN
  description: >-
    Phase II obstetric APS trial evaluating adjunct hydroxychloroquine with
    conventional aspirin and low-molecular-weight heparin management to improve
    uncomplicated term pregnancy.
  target_phenotypes:
  - preferred_term: Preterm Birth
    term:
      id: HP:0001622
      label: Premature birth
  - preferred_term: Preeclampsia
    term:
      id: MONDO:0005081
      label: preeclampsia
  evidence:
  - reference: clinicaltrials:NCT04275778
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: The objective of this clinical trial is to evaluate the benefit of addition or no of hydroxychloroquine to conventional treatment in obstetric APS.
    explanation: This supports an interventional obstetric APS trial testing hydroxychloroquine as adjunct therapy.
datasets:
- accession: DOI:10.1002/art.42947
  title: A Genome-Wide Association Study Suggests New Susceptibility Loci for Primary Antiphospholipid Syndrome
  description: >-
    Large genome-wide association study resource for primary APS, used to
    identify susceptibility loci and compare the genetic architecture of APS
    with other immune-mediated diseases.
  organism:
    preferred_term: human
    term:
      id: NCBITaxon:9606
      label: Homo sapiens
  data_type: GWAS
  sample_count: 5485
  conditions:
  - primary antiphospholipid syndrome
  - immune-mediated disease genetic comparison
  publication: PMID:38973605
  evidence:
  - reference: PMID:38973605
    reference_title: "A Genome-Wide Association Study Suggests New Susceptibility Loci for Primary Antiphospholipid Syndrome."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "METHODS: We performed a genome-wide association study comprising 5,485 individuals (482 affected individuals) of European ancestry."
    explanation: This supports the cohort size and GWAS design of a major primary APS genetics dataset.
- accession: DOI:10.1136/annrheumdis-2013-204600
  title: Gene profiling reveals specific molecular pathways in the pathogenesis of atherosclerosis and cardiovascular disease in antiphospholipid syndrome, systemic lupus erythematosus and antiphospholipid syndrome with lupus
  description: >-
    Human monocyte microarray dataset comparing APS, APS plus SLE, SLE, and
    healthy donors to define inflammatory, atherosclerotic, and prothrombotic
    transcriptional programs.
  organism:
    preferred_term: human
    term:
      id: NCBITaxon:9606
      label: Homo sapiens
  data_type: MICROARRAY
  sample_types:
  - preferred_term: peripheral blood monocytes
    term:
      id: UBERON:0000178
      label: blood
    cell_type_term:
      preferred_term: monocyte
      term:
        id: CL:0000576
        label: monocyte
    tissue_term:
      preferred_term: blood
      term:
        id: UBERON:0000178
        label: blood
  sample_count: 190
  conditions:
  - primary antiphospholipid syndrome
  - antiphospholipid syndrome associated with systemic lupus erythematosus
  - systemic lupus erythematosus
  - healthy controls
  publication: PMID:24618261
  evidence:
  - reference: PMID:24618261
    reference_title: "Gene profiling reveals specific molecular pathways in the pathogenesis of atherosclerosis and cardiovascular disease in antiphospholipid syndrome, systemic lupus erythematosus and antiphospholipid syndrome with lupus."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "METHODS: 129 patients (42 APS, 31 APS plus SLE and 56 SLE) and 61 healthy donors were included. Microarray expression profiling was performed in monocytes."
    explanation: This supports a disease-relevant monocyte transcriptomic dataset spanning APS and overlapping autoimmune comparator groups.
- accession: DOI:10.3389/fimmu.2021.702425
  title: Urine Proteomics Differentiate Primary Thrombotic Antiphospholipid Syndrome From Obstetric Antiphospholipid Syndrome
  description: >-
    Urine proteomics dataset distinguishing primary thrombotic APS from primary
    obstetric APS using iTRAQ and liquid chromatography-tandem mass spectrometry.
  organism:
    preferred_term: human
    term:
      id: NCBITaxon:9606
      label: Homo sapiens
  data_type: PROTEOMICS
  sample_types:
  - preferred_term: urine sample
    term:
      id: UBERON:0001088
      label: urine
    tissue_term:
      preferred_term: urine
      term:
        id: UBERON:0001088
        label: urine
  sample_count: 39
  conditions:
  - primary thrombotic antiphospholipid syndrome
  - primary obstetric antiphospholipid syndrome
  - healthy controls
  publication: PMID:34489952
  evidence:
  - reference: PMID:34489952
    reference_title: "Urine Proteomics Differentiate Primary Thrombotic Antiphospholipid Syndrome From Obstetric Antiphospholipid Syndrome."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: Urine samples from 15 patients with TAPS, 9 patients with OAPS, and 15 healthy controls (HCs) were collected and analyzed using isobaric tags for relative and absolute quantification (iTRAQ) labeling combined with liquid chromatography-tandem mass spectrometry analysis to identify differentially expressed proteins.
    explanation: This supports a human APS proteomics dataset spanning thrombotic and obstetric primary APS subgroups.
review_notes: Antiphospholipid syndrome is an autoimmune disorder characterized by thrombosis (both venous and arterial) and pregnancy complications due to autoantibodies against phospholipid-binding proteins. This update adds evidence-backed pulmonary embolism and stroke phenotypes, documents catastrophic APS as a severe subtype, and adds standard treatment coverage for long-term anticoagulation, obstetric APS management, and adjunct hydroxychloroquine.
disease_term:
  preferred_term: antiphospholipid syndrome
  term:
    id: MONDO:8000010
    label: antiphospholipid syndrome
classifications:
  harrisons_chapter:
  - classification_value: hematologic disorder
    evidence:
    - reference: PMID:20822807
      reference_title: "Antiphospholipid syndrome."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: Other clinical manifestations are cardiac valvular disease, renal thrombotic microangiopathy, thrombocytopenia, haemolytic anaemia, and cognitive impairment.
      explanation: APS has prominent hematologic manifestations, including thrombocytopenia and hemolytic anaemia.
  - classification_value: coagulation disorder
    evidence:
    - reference: PMID:10763209
      reference_title: "[Aspirin and antiphospholipid syndrome]."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: Antiphospholipid syndrome is the most frequent cause of acquired thrombophilia.
      explanation: Acquired thrombophilia places APS within coagulation disorders.
  - classification_value: autoimmune disease
    evidence:
    - reference: PMID:16394638
      reference_title: "[Catastrophic antiphospholipid syndrome: CAPS]."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: Antiphospholipid syndrome (APS) is well known as an autoimmune thrombotic syndrome with recurrent thromboses.
      explanation: This review explicitly describes APS as an autoimmune syndrome.